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SUMMARY 
SUMMARY 
Acute Kidney Injury (AKI) is a complex clinical syndrome which presents very high morbidity and 
mortality rates in developed countries. Despite the intense research of the last decades, AKI 
diagnosis and therapeutic approaches have undergone few advances, probably due to the fact that 
current clinical tools offer late diagnosis information. Identification of new molecular mechanisms 
involved in AKI pathophisiology is essential for development of new diagnostic and prognostic tools 
as well as discovery of new therapeutic targets.  
microRNAs (miRNAs) are post-transcriptional regulators of almost every cellular process. They have 
been unveiled as fine-tuners of genetic information and accumulating evidence has demonstrated 
that they are at the bases of the pathophysiological mechanism of a wide range of disorders, 
including nephropaties.  
In this work, we have identified and characterized several miRNAs as key mediators of the proximal 
tubule response to I/R injury. Moreover we have point out these miRNAs as AKI diagnostic, 
prognostic and predisposition biomarkers.  
For this purpose, we have used an in vivo model of renal ischemia/reperfusion in rat as well as an in 
vitro model in proximal tubule cells which closely mimics the stimuli and features observed in vivo. 
Additionally, we have used serum samples of AKI patients from two cohorts: Intensive Care Unit 
patients and cardiac surgery patients.  
Using these experimental models of I/R and by means of microarrays and qRT-PCR analysis, we 
demonstrated that miR-127 is modulated during ischemia and also during reperfusion, in vivo and in 
vitro. In vitro interference approaches demonstrated that ischemic induction of miR-127 is mediated 
by Hypoxia Inducible Factor-1alpha (HIF-1α) stabilization.  
Moreover, miR-127 is involved in cell-matrix and cell-cell adhesion maintenance, since 
overexpression of miR-127 maintains focal adhesion complex assembly and tight junctions’ integrity. 
miR-127 also regulates intracellular trafficking. In fact, we have identified for the first time in this 
work the Kinesin Family Member 3B (KIF3B), key molecule in cell trafficking, as a target of miR-127 in 
rat proximal tubule cells.  
Moreover, since miRNAs can be detected in extracellular body fluids, and based in our findings using 
experimental models, we have identified and validated a panel of 10 serum miRNAs, including miR-
127, as biomarkers of AKI in patients.  
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An initial screening experiment led to a panel of serum miRNAs which were validated in bigger 
cohorts of ICU patients with AKI and patients who underwent cardiac surgery with cardiopulmonary 
bypass.  
Validation experiments demonstrated that our panel of miRNAs are powerful diagnostic biomarkers 
of AKI with sensitivity and specificity close to 100%. Moreover, serum miRNAs detect AKI 
development before serum creatinine increases, becoming early diagnostic tools.  
Serum miRNAs provide additional valuable clinical information since miRNA levels in serum correlate 
with AKI grade and can distinguish between pre-renal and intrinsic AKI origin as well as among AKI 
etiologies. Moreover, serum miRNAs levels estimated before surgery can predict AKI development 
later on, becoming biomarkers of AKI predisposition.  
RESUMEN 
La insuficiencia renal aguda (IRA) es un síndrome clínico complejo que presenta una alta tasa de 
morbilidad y mortalidad en los países desarrollados. A pesar de la intensa investigación de las últimas 
décadas, los métodos de diagnóstico del daño renal y su terapéutica han experimentado pocos 
avances, probablemente debido a que las herramientas clínicas actuales ofrecen una información de 
diagnóstico tardía. La identificación de nuevos mecanismos moleculares implicados en la 
patofisiología de la IRA es esencial para el desarrollo de nuevas herramientas de diagnóstico y el 
descubrimiento de nuevas dianas terapéuticas.  
Los microRNAs son reguladores post-transcripcionales implicados prácticamente en todos los 
procesos celulares. Son reguladores finos de la información genética y crecientes evidencias ha 
demostrado que están implicados en los mecanismos fisiopatológicos subyacentes a numerosas de 
enfermedades, incluyendo nefropatías.  
En este trabajo hemos identificado y caracterizado varios miRNAs como mediadores clave de la 
respuesta del túbulo proximal al daño por Isquemia/Reperfusión (I/R). Así mismo, hemos desvelado 
el papel de estos miRNAs como biomarcadores diagnósticos, pronósticos y de predisposición de IRA.  
Para ello hemos utilizado un modelo in vivo de I/R renal en rata, así como un modelo in vitro en 
células proximales tubulares que reproduce todos los estímulos y eventos observados in vivo. 
Adicionalmente, hemos utilizado muestras de suero de pacientes con IRA procedentes de dos 
cohortes: Pacientes de unidades de cuidados intensivos y pacientes sometidos a cirugía cardiaca. 
Utilizando estos modelos experimentales de I/R y por medio de microarrays y análisis mediante qRT-
PCR, hemos demostrado que miR-127 se modula durante isquemia y también durante la reperfusión 
tanto in vivo como in vitro. Experimentos de interferencia in vitro demostraron que la inducción 
isquémica de miR-127 es mediada por la estabilización del Factor Inducible por Hipoxia-1α (HIF-1α).  
Así mismo, miR-127 está implicado en el mantenimiento de la adhesión célula-célula y célula-matriz, 
ya que la sobreexpresión de miR-127 mantiene el ensamblaje de los complejos de adhesión focal y la 
integridad de las uniones estrechas. miR-127 regula también el tráfico intracelular. De hecho, hemos 
identificado por primera vez en este trabajo el miembro 3B de la familia de la Kinesina (KIF3B), 
molécula clave para el tráfico intracelular, como una diana real de miR-127 en células proximales 
tubulares de rata.  
Así mismo, como los miRNAs pueden ser detectados en fluidos corporales extracelulares, y 
basándonos en nuestros resultados obtenidos en modelos experimentales, hemos identificado y 
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validado un panel de 10 miRNAs en suero, incluyendo miR-127, como biomarcadores de IRA en 
pacientes.  
Un experimento de cribado inicial llevó a la selección de un panel de miRNAs en suero que fueron 
posteriormente validados en una cohorte de pacientes de UCI con daño renal, así como en una 
cohorte de pacientes de cirugía cardiaca con circulación extracorpórea.  
Los experimentos de validación demostraron que nuestro panel de miRNAs en suero son 
biomarcadores diagnósticos de IRA con una especificidad y sensibilidad cercana al 100%. Además, los 
miRNAs séricos pueden detectar el desarrollo de IRA antes que el incremento de creatinina, 
demostrando que son herramientas de diagnóstico precoz.  
Los miRNAs séricos proporcionan información clínica adicional valiosa, ya que los niveles de miRNAs 
en suero correlacionan con la severidad del daño renal y pueden discriminar entre daño renal de 
origen renal o pre-renal, así como entre sus etiologías. Así mismo, los niveles de miRNAs en suero, 
estimados antes de la cirugía, pueden predecir el desarrollo posterior de daño renal, lo que 
demuestra su valor como biomarcadores de predisposición de IRA.  
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1 ABBREVIATIONS 
 ADQI: Acute Dialysis Quality Initiative. 
 AJ: Adherent Junctions. 
 AKI: Acute Kidney Injury. 
 AKIN: Acute Kidney Injury Network. 
 ANOVA: Analysis of variance.  
 ARF: Acute Renal Failure. 
 ATN: Acute Tubular Necrosis. 
 ATP: Adenosine tri-phosphate. 
 AUC: Area under the curve. 
 BMI: Body mass Index. 
 BSA: Bovine serum albumin. 
 CBP: CREB Binding protein. 
 CC: Nutrient depletion control condition. 
 cDNA: copy DNA. 
 ChIP: Chromatin Immunoprecipitation. 
 CI: Cell index. 
 CKD: Chronic kidney disease. 
 CNSs: conserved non coding sequences. 
 CPB: Cardiopulmonary bypass. 
 Cq: Quantification crossing points. 
 Crs: Serum Creatinine. 
 DAPI: 4',6-diamidino-2-phenylindole. 
 DAVID: Bioinformatic Database for Annotation, Visualization and Integrated Discovery. 
 Dfx: Deferoxamine. 
 DMEM: Dulbecco's modified Eagle's medium 
 DNA: Deoxyribonucleic acid. 
 DTT: Dithiothreitol. 
 ECM: Extracellular Matrix. 
 eCrCl: Creatinine clearance. 
 EDTA: Ethylenediaminetetraacetic acid 
 eIF4F: eukaryotic translation-initiation complex 4F. 
 EPO: Erythropoietin. 
 ESRD: End-Stage Renal disease. 
 FAC: Focal Adhesion Complex. 
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1 ABBREVIATIONS 
 FAK: Focal Adhesion Kinase. 
 FBS: Fetal Bovine Serum. 
 FDA: Food and Drug Administration. 
 FITC: fluorescein isothiocyanate. 
 GFR: Glomerular Filtration Rate. 
 GO: Gene ontology database. 
 H/R: Hypoxia/Reoxygenation. 
 HBS: HIF binding sites. 
 HBSS: Hank's Buffered Salt Solution. 
 HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid. 
 HIF: Hypoxia Inducible Factor. 
 HK-2: Human kidney proximal tubule epithelial cell line. 
 HRE: Hypoxia Response Elements. 
 hsa-miRNA: Homo sapiens microRNA. 
 Hyp CM: Hypoxia in complete medium. 
 Hyp MM: Hypoxia in minimum medium. 
 I/R: Ischemia/Reperfusion. 
 ICU: Intensive Care Unit. 
 IgG: Immunoglobulin G.  
 IL-18: Interleukin-18. 
 KDa: KiloDalton 
 KDIGO: Kidney Disease: Improving Global Outcomes. 
 KEGG: Kyoto Encyclopedia of Genes and Genomes database. 
 KIF3B: Kinesin Family member 3B. 
 KIM-1: Kidney Injury Molecule-1. 
 KO: Knockdown. 
 LNA: Locked Nucleic Acid. 
 MAPK-4: Mitogen activated protein kinase 4. 
 MDRD: Modification of diet in renal disease formula.  
 miRNA: microRNA. 
 mRNA: Messenger RNA.  
 MVB: Multivesicular bodies. 
 NGAL: Neutrophil Gelatinase-Associated Lipocalin. 
 NRK-52E: Normal Rat Kidney proximal tubule epithelial cell line. 
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1 ABBREVIATIONS 
 Nx: Normoxia. 
 PABPC: Cytoplasmic poly-A Binding Protein.  
 PBS: Phosphate buffered saline. 
 PCR: Polymerase chain reaction. 
 PHD: Prolyl-4 hydroxylases domain enzymes. 
 PMSF: phenylmethylsulfonyl fluoride. 
 PSSM: Position specific scoring matrix. 
 qRT-PCR: Quantitative real time PCR. 
 RIFLE: acronym indicating Risk of renal dysfunction; Injury to the kidney; Failure of kidney 
function; Loss of kidney function and End-Stage Kidney Disease). 
 RISC: RNA Induced Silencing Complex. 
 RNA: Ribonucleic acid.  
 rno-miRNA: Rattus norvegicus microRNA. 
 ROC: Receiver-Operator Characteristic curve. 
 RRT: Renal Replacement Therapy. 
 RTCA: Real Time Cell Analyzer. 
 s.e.m.: Standard error of the mean. 
 SDS: Sodium dodecyl sulfate. 
 SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
 siRNA: short interfering RNA. 
 TGF-β: Tumor Growth Factor-β. 
 TJ: Thigh Junctions. 
 UTR: Untranslated Region. 
 VEGF: Vascular Endothelial Growth Factor. 
 ZO-1: zonula occludens-1. 
 ΔCrs: Creatinine increment.     
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1. - Acute Kidney Injury (AKI):  
1.1. - Definition:  
Acute Renal Failure (ARF) is a clinical syndrome characterized by a drastic loss of renal function, 
which alters body homeostasis. It is frequently associated with decreased diuresis and an increase of 
nitrogen products in blood (Abuelo JG, 2007; Liaño F et al., 2011). 
 However, despite this traditional definition, recent studies have demonstrated that small changes in 
glomerular filtration rate (GFR) and, consequently serum creatinine levels, have a significant impact 
on mortality risk (Chertow GM et al., 2005). For this reason, the formerly used term ARF has been 
replaced by Acute Kidney Injury (AKI). AKI is a more extended concept which includes the broad 
spectrum of this syndrome from minor changes in renal function to renal replacement therapy (RRT) 
requirement (Srisawat N et al., 2010). 
AKI is a complex disorder that is often under-recognized and entails severe consequences. It presents 
a wide range of etiologies and risk factors and reaches a very high mortality rate, especially when 
dialysis is required. Depending on its pathophysiological origin, AKI can be classified as pre-renal, due 
to a poor kidney perfusion, intrinsic, if the alteration is located in renal parenchyma, or obstructive if 
there is a problem in urine elimination (Liaño F et al., 2011). On the other hand, AKI can present 
different etiologies, depending on the cause of kidney injury. Thus, AKI can be classified as ischemic, 
septic or toxic etiology when damage is produced by an ischemic insult, a systemic septic response or 
a nephrotoxic compound respectively (Liaño F et al., 2011).  
Despite the understanding and knowledge of the pathophysiological mechanisms has significantly 
increased during the last decades, translation of this knowledge from bench to the clinical practice to 
improve patient management and outcome has been limited.  
The lack of a universal definition and classification of AKI is a significant limitation for clinical practice. 
Thus several efforts have been done to solve this problem and several definitions and classifications 
have been proposed.  
 
1.2. - AKI Classifications:  
Before 2004 there was no consensus on the diagnostic criteria or clinical definition of AKI and more 
than 30 different definitions could be found in the literature (Mehta RL and Chertow GM, 2003). This 
year, the Acute Dialysis Quality Initiative (ADQI), a world panel of experts, developed by consensus 
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criteria the RIFLE classification (acronym indicating Risk of renal dysfunction; Injury to the kidney; 
Failure of kidney function; Loss of kidney function and End-Stage Kidney Disease). The aim of this 
classification was to standardize AKI definition for clinical practice and research purposes (Bellomo R 
et al., 2004; Srisawat N et al., 2010; Srisawat N et al., 2011).   
 
RIFLE Classification:  
The RIFLE classification is a multilevel system in which is included a wide range of disease spectra. It 
presents three levels of renal dysfunction (Risk, Injury and Failure) and also two clinical outcomes 
(loss of renal function and End-Stage kidney disease).  
The three severity grades are defined based on changes in serum creatinine, GFR or urine output, 
were the worst criteria must be used for classification. The two outcome criteria are defined by 
duration of loss of kidney function. Persistent AKI (loss) is defined as need for RRT for more than 4 
weeks, whereas ESRD is defined by need of dialysis for more than 3 months (Bellomo R et al., 2004; 
Srisawat N et al., 2011). Classification settings can be found in detail in Table 1.  
The RIFLE classification has been validated in more than 550.000 patients around the world (Srisawat 
N et al., 2011). It has demonstrated its utility not only for AKI diagnosis and patient classification but 
also as prognosis and evolution marker of AKI in several clinical contexts such as Intensive Care Units 
(ICU), cardiac surgery patients and pediatric population, where some criteria have been modified 
(Akcan-Arikan A et al., 2007; Liaño F et al., 2011).  
However, despite these advantages, several publications have identified the weak points of this 
classification:  
1) There is no concordance among the criteria used in each category, for instance a 150% increase 
of serum creatinine correlates with a 33% decrease in glomerular filtration rate (GFR) instead of 
25% proposed in R level (Pickering JW and Endre ZH, 2009a).  
2) Estimation of basal creatinine, when unknown, by the “modification of diet in renal disease” 
(MDRD) formula considering GFR of 75 ml/min is not useful in a clinical context because this 
equation requires a steady-state condition to be applied, something that is not easily found in 
ICU patients, especially in those with AKI (Liaño F et al., 2011).  
3) Urine output is difficult to obtain out of the ICU context, were patients are not probed (Liaño F et 
al., 2011).  
4) Hydration state or diuretics are not taken into account as modifier factors (Liaño F et al., 2011).  
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5) Glomerular filtration is only indirectly linked to renal disease and changes in GFR can be a late 
consequence of accumulative primary injuries to the kidney. Moreover, a large amount of renal 
mass can be lost without changes in GFR due to the “renal reserve” (Vaidya VS and Bonventre JV, 
2010).  
 
AKIN Classification: 
As previously indicated, several studies have evidenced that small changes in serum creatinine levels 
are associated with adverse outcomes and increase of short and long-term morbidity and mortality 
(Lassnigg A et al 2004; Chertow GM et al., 2005;). Based on this evidence and due to the limitations 
of the RIFLE classification, in 2007 the Acute Kidney Injury Network (AKIN), a panel of 
multidisciplinary international experts with the support of scientific societies, proposed a new 
classification modifying some of the RIFLE criteria (Mehta RL et al., 2007).  
This classification modifies AKI definition, including a 48 hours period for diagnosis that was not 
taken into account in RIFLE classification, where seven days of observation was proposed, although is 
not directly indicated in the original publication (Mehta RL et al., 2007; Liaño F et al., 2011). AKI is 
defined as “An abrupt (within 48 hours) reduction in kidney function currently defined as an absolute 
increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 μmol/l), a percentage 
increase in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduction in 
urine output (documented oliguria of less than 0.5 ml/kg per hour for more than six hours)”.  
The AKIN modifications proposed three numeric stages for severity (1, 2 and 3 instead of R, I and F). 
In this classification, stage 1 increases the R category of RIFLE including patients with smaller increase 
of serum creatinine (≥ 0.3 mg/dl). Grade 2 corresponds with I stage and each patient who requires 
RRT is directly included in grade 3, independently of creatinine levels or diuresis (Mehta RL et al., 
2007; Liaño F et al., 2011; Srisawat N et al., 2011). Classification criteria are summarized in Table 1. 
The AKIN classification has demonstrated increased sensitivity, especially when the studied 
population includes a high rate of chronic kidney disease (Srisawat N et al., 2011). However, some 
works comparing RIFLE and AKIN classifications indicate similar sensitivity in ICU patient studies 
(Bagshaw SM et al., 2008) whereas other studies reveal that RIFLE classification includes 10% more 
patients than AKIN (Joannidis M et al., 2009).  
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Table 1: Clinical criteria used for different AKI Classifications. 
RIFLE (Adults) 
Level Creatinine Increase GFR Decrease Urine Output 
R (Risk) sCr x 1.5 > 25% <0.5 ml/kg/h for 6 h 
I (Injury) sCr. X 2 >  50% <0.5 ml/kg/h for 12 h 
F (Failure) sCr x 3 or sCr ≥ 4 
mg/dl with increase 
of ≥ 0.5mg/dl 
>  75% <0.3 ml/kg/h for 24 h 
or 12 h anuria 
L (Loss) Need of RRT for more than 4 weeks 
ESRD Need of RRT for more than 3 months 
sCr: Serum Creatinine. ESRD: End-stage renal disease. Changes observed in 7 days 
RIFLE (Pediatric) 
Level eCrCl Decrease Urine Output 
R (Risk) > 25% <0.5 ml/kg/h for 6 h 
I (Injury) > 50% <0.5 ml/kg/h for 16 h 
F (Failure) > 75% or 
eCrCl < 35/ml/min/1.73 m2 
<0.3 ml/kg/h for 24 h or 12 h 
anuria 
eCrCl: Creatinine clearance stimated by Schwartz formula. 
AKIN  
Level Creatinine Increase Urine Output 
1 Crs x 1.5 or  ΔCrs ≥ 0.3 mg/dl <0.5 ml/kg/h for 6 h 
2 Crs. X 2 <0.5 ml/kg/h for 12 h 
3 Crs x 3 or Crs ≥ 4 mg/dl with 
increase of ≥ 0.5mg/dl. 
or RRT Patients 
<0.3 ml/kg/h for 24 h or 12 h 
anuria 
RRT: Renal Replacement Therapy. Changes observed in 48 hours. 
Creatinine Kinetics 
Level Δ Crs in 24 h Δ Crs in 48 h 
1 0.3 mg/dl 0.5 mg/dl 
2 0.5 mg/dl 1 mg/dl 
3 1 mg/dl 1.5 mg/dl 
KDIGO 
Level Creatinine Increase Urine Output 
1 1.5–1.9 times baseline or ≥0.3 
mg/dl 
<0.5 ml/kg/h for 6–12 hours 
2 2.0–2.9 times baseline <0.5 ml/kg/h for ≥12 hours 
3 3.0 times baseline or ≥4.0 
mg/dl or RRT 
<0.3 ml/kg/h for ≥24 hours or 
Anuria for ≥12 hours 
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Creatinine Kinetics Classification:  
It has been recently questioned if the use of percentage changes of serum creatinine is the correct 
criteria for AKI diagnosis. A mathematical model of creatinine kinetics have demonstrated that 
absolute changes in serum creatinine directly reflects changes in GFR quicker than percentage 
changes, especially in patients with Chronic kidney disease (CKD). This creatinine kinetics 
classification proposes three stages based on absolute changes in serum creatinine (0.3 mg/dl, 0.5 
mg/dl, 1 mg/dl and 1.5 mg/dl) produced in defined time-periods of 24 and 48 hours  (Waikar SS and 
Bonventre JV, 2010; Liaño F et al., 2011) (Table 1).  
This classification appears to be more sensitive in patients with previous CKD. However, it does not 
take into account the effects of RRT in serum creatinine levels and it does not considerate diuresis as 
diagnosis criteria (Liaño F et al., 2011).  
 
KDIGO Classification: 
In order to advance in the process of AKI classification, a new approach has been developed in the 
KDIGO (Kidney Disease: Improving Global Outcomes) classification. This classification combined the 
criteria of AKIN and RIFLE definitions and AKI is diagnosed as follows (Not Graded):  
 Increase in SCr by ≥0.3 mg/dl (≥26.5 lmol/l) within 48 hours; or 
 Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within 
the prior 7 days; or 
 Urine volume <0.5 ml/kg/h for 6 hours. 
AKI severity is staged following the criteria showed in Table 1 (Khwaja A, 2012; KDIGO Guidelines). 
Due to their recent development, this classification has not been used in this work. Further studies of 
our group will include also these diagnosis criteria. 
 
All these classifications have supposed a great step forward in AKI definition, patient classification 
and in prediction of patient mortality or renal function recovery. However, all of them have common 
drawbacks because they are based in serum creatinine, a renal function biomarker that increases its 
levels lately and does not directly reflect the moment of the injury and the damaged kidney 
compartment. Indeed, several new biomarkers for renal dysfunction have been assayed in the last 
years, as we will further comment in next sections of this work.  
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1.3. – AKI Epidemiology:  
AKI epidemiology, including incidence, prognosis and outcome is difficult to assess because the 
number of cases can drastically change depending on the used definition, measured parameters 
(serum creatinine or both serum creatinine and urine output), differences in baseline GFR estimation 
and study ending time-points  (in hospital mortality, 30 days, 60 days or 6 months). Incidence and 
outcome also vary depending on the patient population (ICU, non-ICU and population-based studies) 
(Srisawat N et al., 2011).  
AKI incidence in population studies was estimated in 550 cases per 100,000 individuals in 2003 (Hsu 
CY et al., 2007) and more recently in 1.811 cases p.m.p. every year (Ali T et al., 2007). A study 
performed by Chertow et al. in 9205 hospitalized patients demonstrated that AKI incidence varies 
from 13% to 1 % depending on the diagnostic criteria employed. Indeed, RIFLE criteria leads to 
incidence estimations from 2% to 7% (Waikar SS et al., 2008) whereas these data increases to 13% 
when AKIN classification is used (Chertow GM et al., 2005).  
Incidence rates are higher in ICU patients where can range from 5% to more than 10%, especially in 
the context of multiorgan failure and sepsis (Waikar SS et al., 2008; Bonventre JV and Yang L, 2011). 
AKI incidence in ICU patients studies including ICU units from 23 countries and 29.269 patients 
estimated AKI incidence in 5.7% (Uchino S et al., 2005).  These data correlate with a study performed 
in 43 UCI units in Spain where AKI incidence was stimated in 5.7% (Herrera-Gutierrez M et al., 2006). 
When RIFLE criteria are applied, AKI incidence in ICU patients can reach 87% (Hoste EA and Schurgers 
M, 2008).  
Despite the great advances in prevention strategies, patient classification and support measures, AKI 
still presents a very high morbidity and mortality, especially in ICU patients where mortality can 
reach 50-70% of the cases. Moreover, AKI survivors present a very high risk of developing chronic 
consequences, such as Chronic Kidney Disease, or accelerated end-stage renal disease development 
(Hsu CY et al., 2009; Bonventre JV and Yang L, 2011).  
The use of a universal classification as well as the development of earlier and more precise 
biomarkers will help to improve AKI epidemiology.  
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2. Biomarkers:  
2.1. – Definition:  
A biomarker is defined as a “characteristic that can be objectively measured and evaluated as an 
indicator of normal biologic processs, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” (Biomarkers definition working group, 2001). Biomarkers can be proteins, 
lipids, electric signals or nucleic acids, among others.  
Following FDA guidelines 2005, a biomarker could be considered valid when: 1) It is measured by an 
analytical test system with well-stablished characteristics, and 2) there is a established scientific 
framework or evidence that elucidates the physiologic, pharmacologic, toxicologic or clinical 
significance of the test result (Vaidya VS and Bonventre JV, 2010).  
Biomarkers are essential for predicting efficacy and toxicity in clinical trials, indicate disease 
susceptibility, earlier disease diagnosis, outcome prediction and to monitor responses to clinical 
interventions even while interventions are going.  Developing of more accurate biomarkers will 
improve patient classification, highlighting different responses to treatments, discovery of new 
therapeutic targets and monitoring severity and disease progression. 
 
2.2. – Characteristics of an Ideal AKI Biomarker:  
The ideal characteristics for a biomarker depend on the context where it is going to be employed. 
Thus a panel of biomarkers for AKI detection should have some common properties to make them 
really useful:  
1) The marker should be sensitive for differentiating among several renal insults. For instance, a 
biomarker could be specific for a determined kidney compartment or cell type, or marker for 
a specific pathological or physiological process. A set of complementary biomarkers could 
offer the advantage of injury localization, solving the ambiguities of traditional markers.  
2) Biomarkers should be sensible and change early, allowing rapid AKI detection and effective 
intervention.  
3) Biomarkers should be kidney specific, reducing the rate of false positive diagnoses. This 
feature is especially important in the context of critically ill patients.  
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4) Biomarkers should be easily accessible and minimally invasive. Accessibility in peripheral 
body fluids makes routine verification easier and avoids the use of more aggressive 
techniques such as biopsies. Moreover, the biomarker should present a great stability in the 
fluid where is detected and also under storage conditions.  
5) The method to detect and quantify the biomarker should be accurate and represent a 
reasonable technical effort. Moreover, cost and time for detection should be taken into 
account.  
(Pepe MS et al., 2001; Etheridge A et al., 2011). 
 
2.3. – Current Biomarkers for AKI diagnosis:  
As was mentioned before, AKI definitions are based in a rapid decrease of renal function, typically 
determined by monitoring serum creatinine levels. Creatinine is a small 113 Dalton molecule derived 
from the metabolism of creatine in skeletal muscle and from dietary meat intake. This molecule is 
released to the plasma in a relative constant rate and is freely filtered in the glomerulus without 
significant reabsorption or metabolism by the kidney (Stevens LA and Levey AS, 2005). Consequently, 
a decrease in GFR leads to a rinse in serum creatinine levels, showing a very well described inverse 
relationship (Kassirer JP, 1971).  
Despite of its widespread use, serum creatinine show important limitations for GFR assessing:  
1) A wide variety of non-renal factors can modify serum creatinine levels, so it is possible to find 
not only differences among patients, but also differences in the same patient in several 
physiological conditions. Age, gender, muscle mass, diet (protein intake) and nutritional 
status are determinant for creatinine production (Bagshaw SM et al., 2008).  
2) In normal kidney function, up to 25% of creatinine is secreted by the tubules directly into 
urine, resulting in GRF overestimation. If GFR is decreased by kidney dysfunction, tubule 
creatinine secretion is increased, resulting again in GFR overestimation. 
3) Several drugs, such as cimetidine, can block creatinine secretion resulting in increased serum 
levels in the absence of kidney injury, limiting its specificity.  
4) Rapid changes in GFR are not visible in real-time by changes in serum creatinine levels, 
because creatinine needs time to accumulate, delaying AKI diagnosis for hours or days. 
(For review Vaidya VS and Bonventre JV, 2010) 
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All these deficiencies in the current standards used in clinical practice point out the urgent need of 
new AKI biomarkers. Early and more sensitive tools will allow application of more effective 
therapeutic and prevention strategies. 
 
2.4. – Principal AKI Biomarkers in Development: 
As described above, the available tools for AKI diagnosis present several deficiencies which have 
encouraged researchers to make an intense effort to discover new AKI biomarkers. Next we describe 
the emerging biomarkers that are currently in development. 
 
Neutrophil Gelatinase-Associated Lipocalin (NGAL): 
NGAL is a 21 kDa member of the lipocalin superfamily of proteins that is expressed in immune cells, 
hepatocytes and renal tubular epithelial cells (Schmit-Ott KM et al., 2007). It was identified in 2003 in 
a transcriptome study to search upregulated genes in response to renal ischemia (Mishra J et al., 
2003). NGAL was unveiled as a potential AKI biomarker because it can be quantified and raises its 
levels in response to kidney injury in human peripheral fluids such as blood and urine.  
NGAL has demonstrated a sensitivity and specificity close to 100% to predict AKI in children 
undergoing cardiac surgery with CPB. Urinary and serum levels of NGAL increased few hours after 
surgery in patients who developed AKI, while serum creatinine levels rose from one to several days 
after intervention (Mishra J et al., 2005). In a similar study in adults, increased levels of NGAL showed 
lower specificity, attributed to different co-factors and associated pathologies (Wagener G et al., 
2006). Similar predictive results can be found in trauma patients (Makris K et al., 2009) and contrast-
induced AKI (Bachorzewska-Gajewska H et al., 2007). Moreover, urine levels could predict delayed 
graft function and RRT requirement in transplant recipients (Parikh CR et al., 2006a; Sirota JC et al., 
2011).  
Despite these promising results, NGAL has only demonstrated high specificity and sensitivity in 
pediatric populations, showing lower diagnostic value in adult studies. In addition, NGAL plasma 
levels are influenced by several variables no related to kidney injury such as systemic infections, 
inflammatory conditions, hypoxia and cancer (Devarajan P. 2010; Mariscalco G et al., 2011) 
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Interleukin-18 (IL-18): 
IL-18 is a 18 kDa, widely expressed, pro-inflammatory cytokine involved in immune response. Several 
studies have identified IL-18 as a mediator of ischemic injury in different organs, including the heart 
and the brain. In the kidney, increased levels of IL-18 protein can be found in tissue and urine after 
ischemic insult (Sirota JC et al., 2011).  
In clinical studies, IL-18 has demonstrated sensitivity to detect AKI in children undergoing 
cardiopulmonary bypass (CPB), increasing its levels between 4-8 hours after intervention (Parikh CR 
et al., 2006b). In the context of kidney transplant, IL-18 has shown increased levels 24 hours after 
intervention predicting delayed graft function (Parikh CR et al., 2006b). It can also differentiate 
between patients with established AKI from other kidney pathologies such as CKD or urinary tract 
infection (Parikh CR et al., 2004). 
However, IL-18 value as AKI biomarker has been challenged in several studies because it does not 
increase its levels in adults which develop AKI after CPB or in contrast-induced nephropathy (Bulent 
Gul CB et al., 2008). Moreover, any inflammatory body response could result in an increase of IL-18 
independently of AKI. Due to this data, IL-18 biomarker value is still controversial and needs further 
investigation (Vaidya VS and Bonventre JV, 2010).  
 
Kidney Injury Molecule-1 (KIM-1): 
KIM-1 is a type-1 transmembrane protein with an immunoglobulin and mucin domain. It is expressed 
in lymphocytes and proximal tubular cells in a low level, but its mRNA and protein drastically increase 
in response to kidney ischemic injury (Vaidya VS et al., 2006; Vaidya VS et al., 2009). This molecule is 
mainly expressed in regenerating proximal tubular cells that are dedifferentiated and proliferating 
(Sirota JC et al., 2011). After protein exposure in membrane, it is cleaved and the ectodomain is 
released into urine (Zhang Z et al., 2007).  
KIM-1 levels are increased in patients with acute tubular necrosis (ATN) and it can be detected not 
only in urine samples, but also by immunohistochemical staining in tissue samples (Han WK et al., 
2002). In the context of adult cardiac surgery, KIM-1 demonstrated low specificity and sensitivity 
values, but the diagnostic capacity of this biomarker increases when is combined with other 
molecules (Koyner JL et al., 2010). More prominent diagnostic potential was found in pediatric 
population submitted to CPB, where KIM-1 increases its levels 12 hours after surgery (Han WK et al., 
2008). Urinary KIM-1 can also predict graft dysfunction and loss in kidney transplant context (Van 
Timmeren MM et al., 2007). Moreover, KIM-1 is expressed and can be detected by 
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immunohistochemistry in transplant biopsies with deterioration of kidney function and tubular 
injury, emerging as a possible new tool for pathologists (Zhang P et al., 2008).  
 
Cystatin C:  
Cystatin C is a 13 kDa protein of the cystatin family, produced by all nucleated cells (Westhuyzen J, 
2006). Serum levels of this protein correlates with GFR better than serum creatinine and its values 
are not influenced by factors like muscle mass, protein intake, age or gender.  
Cystatin C is freely filtered by the glomerulus and nearly completely reabsorbed by proximal tubules. 
Thus, increased levels of Cystatin C in urine reflect proximal tubule injury instead of glomerular 
dysfunction (Uchida K and Gotoh A, 2002; Conti M et al., 2006).  
Cystatin C seems to be an early biomarker of AKI compared to serum creatinine (Herget-Rosenthal S 
et al., 2004). Indeed, several studies have demonstrated that urinary cystatin C can successfully 
predict AKI in the context of adult cardiac surgery (Koyner JL et al., 2008) and ICU patients (Nejat M 
et al., 2010). This biomarker can also predict delayed graft function in kidney transplant receptors 
and the urine cystatin C/Creatinine ratio during the first post-surgery days correlates with long-term 
graft function (Hall IE et al., 2011; Sirota JC et al., 2011). However, despite of this evidence, several 
works indicate that serum levels of cystatin C are a reliable marker of function, instead of a true 
biomarker for injury (Herget-Rosenthal S et al., 2004). 
 
Despite the promising results observed for all these biomarkers, they still present several 
disadvantages that need to be solved to truly demonstrate their clinical value. One of the most 
significant problems is that, although some of them successfully predict AKI in pediatric population, 
they fail in adult studies, where other associated pathologies can be found. Due to these limitations, 
researchers are looking for new molecules with improved diagnostic potential, as we have done in 
this work.  
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3. Circulating microRNAs (miRNAs) as Novel Biomarkers:  
miRNAs are small (20-25 nucleotides) endogenous RNA molecules which post-transcriptionally 
regulate gene expression and are involved in almost every cellular process (Krol J et al., 2010b). 
Despite of the previous hypothesis which postulated that miRNAs were only present inside the cell, it 
has been recently demonstrated that they can also be secreted to the extracellular environment with 
potential functional consequences (Février B and Raposo G, 2004). This secretion process makes 
them suitable to be detected in a wide range of cell-free body fluids such as breast milk, urine or 
serum (Fleischhacker M and Schmidt B, 2007). 
miRNA secretion seems a highly regulated process and selection of miRNAs is a directed and non-
random process. On the other hand, miRNA deregulation has been associated with the appearance 
and development of a wide range of pathologies. Due to these features, physiological or pathological 
regulation of intracellular miRNAs may also modify the panel of secreted miRNAs. Indeed, changes in 
serum miRNAs profiles have been unveiled as biomarkers of a wide range of diseases such as cancer, 
cardiovascular disease, stroke and multiple sclerosis, as well as altered physiological states such as 
pregnancy (for review Reid G et al., 2011).  
Moreover, serum miRNAs have demonstrated great stability and resistance to aggressive conditions 
such as RNAse treatment, or drastic pH changes (Chen X et al., 2008). The mechanism underlying this 
unexpected miRNA stability in serum is not completely understood yet, but it has been 
demonstrated that circulating microRNAs are released from cells in membrane vesicles which 
protects them from the environment. Vesicles proposed to be carriers of circulating microRNAs 
include exosomes, which are 50-90 nm vesicles released by exocytosis from multivesicular bodies 
(MVB) (Février B and Raposo G, 2004; Kosaka N et al., 2010,) as well as larger microvesicles up to 1 
µm (Hunter MP et al., 2008; Gallo A. et al., 2010). However, recent studies have demonstrated that 
serum circulating miRNAs can also be carried by Argonaute2 proteins (Arroyo JD. et al., 2011). 
Taken together, all these features demonstrate that serum circulating miRNAs achieve nearly all the 
necessary characteristics for an ideal biomarker, as described before. Their presence in a peripheral 
fluid allows diagnosis by minimum invasive methods and serum samples can be easily and routinely 
obtained in clinical practice.  In addition to their high stability in fresh serum, several studies have 
demonstrated that miRNAs maintains stability and reliability in long-term stored serum samples and 
in samples conserved at room temperature for hours (Chen X et al., 2008). Moreover, they can be 
easily quantified with relative low price and technical effort by qRT-PCR. These characteristics, join to 
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their great tissue and cell type specificity, have unveiled circulating miRNAs as promising biomarkers 
for more accurate diagnosis and monitoring of diseases.  
 
4. – Renal Ischemia/Reperfusion Injury and Recovery: 
 
Renal ischemia/Reperfusion (I/R) injury is one of the principal and more frequent causes of AKI (Liaño 
F and Pascual J, 1996). I/R is produced by a generalized or localized impairment of oxygen and 
nutrient supply to the kidney that can occur as a consequence of many pathophysiological 
conditions, like hemorrhage or sepsis, pharmacological treatments or clinical interventions, such as 
CPB and renal transplant (Bonventre JV and Yang L, 2011).  
Although all kidney compartments are affected by I/R injury, proximal tubule epithelial cells are 
specially sensitive to lack of oxygen and nutrient supply due to their intrinsic characteristics 
(Gunaratnam L and Bonventre JV, 2009).  
 
4.1. - Proximal tubule cells: 
Proximal tubule cells are epithelial cells which present some metabolic and functional particularities 
due to their high specialization and the challenging environment where they are located:  
1) Cell Cohesion: epithelial cells present a strong cellular adhesion network involved in 
epithelium stability, mechanotransduction, epithelial barrier impermeability and cell 
communication.  
2) Adhesion to basement membrane: basement membrane is principally composed by collagen 
IV and glicoproteins and it is responsible for separating epithelial cells from connective 
tissue.  
3) Non-vascular tissue: epithelia do not present blood vessels, thus its metabolism depends on 
oxygen and nutrient diffusion from connective tissue, located under basement membrane.  
4) Polarization: proximal tubule cells are markedly polarized. They present an apical pole with a 
developed brush border to improve reabsorption of substances from urine. Basal pole is in 
contact with basement membrane and presents a great number of cell-matrix adhesion 
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structures. This marked polarity determines organelles distribution inside the cell and the 
diverse functions of plasma membrane in the different parts of the cell.  
(For review Alberts B, 2007) 
 
4.1.1. – Proximal Tubule Cell Adhesion Complexes:  
As mentioned above, proximal tubule cells present two major types of cell adhesions: cell-to-cell 
and cell-to-extracellular matrix (ECM) (Figure 1A). Both structures are generally composed by a 
transmembrane cell adhesion molecule, intracellular scaffold or signaling proteins and 
cytoskeleton components. 
 
 Figure 1: Epithelial cells adhesion structures. (A) Cell-Cell and Cell-Matrix adhesion 
structures location in epithelial cells (Red bars: actin filaments; Purple lines: intermediate 
filaments). (B) Molecular components of adherent junctions. (C) Molecular components of 
tight junctions. (D) Molecular components of focal adhesion complexes. Modified from 
Kawauchi T, 2012.  
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Proximal tubule cell-cell adhesion is mainly carried out by Adherent Junctions (AJ) and Thigh 
Junctions (TJ): 
AJ are responsible of physical association of cells in a calcium-dependent manner. Cadherins are 
transmembrane proteins which are essential in these adhesive structures. Classical cadherins 
present an extracellular domain which provides trans-homophilic binding to other cadherins on 
neighboring cells, and their intracellular domains directly interact with β-catenin. α-catenin binds 
both β-catenin and several actin-binding proteins, such as vinculin and EPLIN. These actin-binding 
proteins regulate the interaction between cadherins and F-actin cooperatively with α- and β-
catenins (Figure 1B) (Kawauchi T, 2012). 
TJ are located at the most apical part of the lateral membranes in epithelial cells (Figure 1A).  
They are composed by a network of sealing strands formed by transmembrane proteins, mainly 
claudins and occludins, embedded in both plasma membranes. Both claudins and occludins bind 
to peripheral membrane proteins including intracellular PDZ domain-containing proteins, ZO-1. 
These peripheral proteins are responsible for anchoring TJ strands to the actin cytoskeleton 
(Figure 1C). In TJ strands, the intercellular distance between two neighboring cells is nearly zero, 
so that the tight junction restricts paracellular diffusion of substances and ions. In addition to the 
selective barrier function, tight junctions separate the plasma membrane into apical and 
basolateral domains to confine the diffusion of transmembrane proteins and lipids to the specific 
membrane domain as a fence (Denker BM and Sabath E, 2011; Kawauchi T, 2012). 
On the other hand, proximal tubule cells are attached to basement membrane by focal adhesion 
complexes (FAC) (Figure 1A). These structures present a receptor molecule called integrin, which 
are transmembrane α–β heterodimers. Their extracellular domain can recognize ECM 
components such as fibronectin, laminin or collagen whereas their intracellular domain binds to 
many scaffold proteins including talin, vinculin, zyxin, focal adhesion kinase (FAK), Src or paxillin. 
These scaffolding proteins join FAC to the F-actin cytoskeleton and are involved in integrin 
activation and signal transduction. FAC not only present a cell-matrix adhesion function, but they 
can also act as a cell signaling center involved in the regulation of cell migration, morphological 
changes, survival and proliferation (Figure 1D) (Kawauchi T, 2012). 
 
4.1.2 - Proximal Tubule Cell Trafficking: 
Proximal tubule cells are responsible for reabsorption of a wide range of substances from 
glomerulus ultrafiltrate, determining urine composition and volume. These cells regulate body 
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fluid, ion and acid/base homeostasis trough the interaction of a great variety of channels, ion 
transporters and pumps within specific tubule segments, specific cells types and specific plasma 
membrane domains (Brown D et al., 2009).  Due to this function, proximal tubule epithelial cells 
present a developed and complex intracellular trafficking activity which is essential for kidney 
function.  
Proximal tubule cells are capable of endocytosis at either of their distinct apical or basolateral 
plasma membrane domains. Endocytosis occurs by both clathrin-dependent and –independent 
mechanism. The postendocytic fate (trafficking steps occurring after internalization) can vary. 
Briefly, the majority of the apically internalized fluid is thought to recycle to apical membrane or 
transcytose to basolateral membranes, but some is delivered to a complex population of late 
endosomes and lysosomes that also receive the majority of basolaterally internalized fluids 
(Apodaca G, 2001).  
Apical endocytosis activity and trafficking is essential for receptor and transporters exposure and 
recycling in apical plasma membrane. Regulation of exposure of transporters plays a key role in 
proximal tubule cells reabsorption and, consequently, in kidney function regulation (Apodaca G, 
2001).  
 
4.1.3 - Proximal Tubule Cytoskeleton and motor proteins: 
The cytoskeleton is crucial for the function of all eukaryotic cells and is required for mitosis, 
cytokinesis, cell motility, cell shape maintenance, endocytosis, and secretion. Epithelial cells 
exploit cytoskeletal elements to ensure efficient targeting of newly synthesized proteins from the 
trans -Golgi network to the appropriate cell surface domain. The cytoskeleton also plays a role in 
endocytosis, exit of cargo from early and late endosomes, and the transport, via transcytosis, of 
endocytosed proteins from one plasma membrane domain to the opposite (Apodaca G, 2001). 
Proximal tubule cells present a developed cortical actin network which is mainly responsible for 
endocytosis and adhesion structures maintenance in the apical membrane. Actin remodelation 
seems to be a regulator of receptor-mediated endocytosis and formation of clathrin coated 
vesicles. On the other hand, actin cytoskeleton is also involved in transcytosis and protein 
delivery to late endosomes and lysosomes.  
In proximal tubule cells, microtubules present a typical parallel organization with their minus 
ends toward the apical surface and their plus ends extending through the cell body to the 
basolateral surface (Hamm-Alvarez SF and Sheetz MP, 1998). Microtubules participate in 
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transcytosis and cargo delivery to endosomes and lysosomes (Apodaca G, 2001). Indeed, 
microtubule cytoskeleton is essential for organelle distribution and apical receptor recycling. 
Microtubule-based motor proteins Kinesin and Dinein play a central role in these distribution 
functions.  
One of these motor proteins is Kinesin-2, a heterotrimeric, plus-end directed motor which 
comprises two motor subunits, KIF3A and either KIF3B or KIF3C, and a non-motor subunit KAP3. 
This complex is ubiquitously expressed and has been involved in the movement of Golgi/ER-Golgi 
intermediate compartment (ERGIC) membranes, Golgi-derived vesicles and late endosomes 
(Brown CL et al., 2005). Moreover, KIF3B, one of the motor subunits of kinesin-2, plays a key role 
in apical membrane receptor recycling in proximal tubule cells. This molecule is involved in the 
regulation of the exposure of kidney anion exchanger 1 (Duangtum N., et al 2011) and 
chloride/proton antiporter CLC-5 (Reed AA et al., 2010).  
 
4.2. - Proximal Tubule Cell Response to I/R Injury: 
As a result of this active intracellular trafficking, ion transporters activity and other ATP-dependent 
metabolic processes, proximal tubule cells have a very high oxygen demand, which make them 
especially sensitive to ischemic injury (Bonventre JV and Yang L, 2011).  
As can be observed in Figure 2, sublethal ischemia results in rapid loss of cytoskeleton organization 
and cell polarity. The brush border quickly breaks down and the apical cortical cytoskeleton is 
disorganized, producing actin relocalization from apical to lateral plasma membrane (Sáenz-Morales 
D et al., 2006). Moreover, ATP depletion leads to intracellular free calcium concentration increase, 
which activates proteases and phospholipases that contribute to cytoskeleton disorganization and 
mitochondrial metabolism impairment (Bonventre JV, 2003).  
ATP depletion and actin cytoskeleton reorganization also results in disruption of cell-cell and cell-
matrix adhesion structures. TJ disruption compromises epithelial barrier function allowing glomerular 
filtrate backleak. Focal adhesion complexes are disassembled causing cell detachment from 
basement membrane and pro-apoptotic signaling (Bonventre JV, 2003; Bonventre JV and Yang L, 
2011).  
Detached epithelial cells and debris combine with proteins of the tubular lumen and fibronectin to 
produce casts that obstruct the tubules increasing I/R injury.  
  
 
48 
 
  
2 INTRODUCTION 
 
Figure 2: Proximal tubule cell response to I/R Injury: damage and repair process. Modified 
from Bonventre JV and Yang L, 2011. 
 
In addition, loss of cell polarity, ATP depletion and cytoskeleton disorganization leads to incorrect 
targeting of membrane proteins such as ion transporters or endocytic receptors, producing proximal 
tubule function impairment (Bonventre JV and Yang L, 2011). 
After injury, surviving proximal tubule cells suffer a dedifferentiation process and drastically increase 
their proliferation rate to refill the gaps produced by detached cells and promote tubule repair. 
Integrins delocalize from basal to lateral membrane contributing to viable cell migration along the 
basement membrane (Bonventre JV and Yang L, 2011). Proximal tubule cell replenishment has been 
a topic of intense debate in the last years. Some studies indicated that repair was carried out by bone 
marrow stromal cells or intrarrenal progenitors, but recent works have demonstrated that surviving 
epithelial cells are responsible for tubule recovery, although they need paracrine signals from bone-
marrow derived cells (Duffield JS et al., 2005; Humphreys BD et al., 2008).  After proliferation and 
migration, tubule cell number is restored and then epithelial cells differentiate, resulting in 
restoration of the functional integrity of the tubule and the nephron (Bonventre JV and Yang L, 
2011).  
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5. – Regulators of Cell Responses to Oxygen: Hypoxia Inducible Factor. 
Oxygen is a key factor that governs important cellular metabolism pathways in aerobic organisms. 
Because of this relevance, cells have developed adaptative and survival mechanism to maintain 
homeostasis in low oxygen tension conditions.  
Hypoxia Inducible Factor (HIF) is the key regulator of cell responses to low oxygen conditions. HIF is a 
heterodimeric transcription factor composed by an α-subunit, which is continuously synthesized and 
degraded in the cytoplasm in normoxic conditions, and a β-subunit, which is non-oxygen sensitive 
and located in the nucleus (Rocha S, 2007).  
Three isoforms have been identified for the α-subunit (HIF-1α, HIF-2α and HIF-3α). HIF-1α and HIF-2α 
isoforms have been extensively studied in the last years. Although there are some coincidences and 
overlapping, both subunits present non-redundant activities driving the expression of different sets 
of genes and being preferentially expressed in different cell types (Rocha S, 2007; Heyman SN et al., 
2011).However, the role and functions of HIF-3α subunit still remains unclear. In this regard, some 
studies postulate a dominant-negative function of HIF transcriptional activity (Heyman SN et al.,  
2011). Two isoforms have been identified for β-subunit, but their biology and functions have not 
been elucidated yet (Brahimi-Horn MC and Pouysségur J, 2009).  
Under normoxic conditions α-subunits are constantly synthesized but not accumulated since they are 
rapidly hydroxylated by oxygen-dependent prolyl-4 hydroxylases domain enzymes (PHD). 
Hydroxylated α-subunits are recognized by Von-Hippel-Lindau protein (VHL), a component of E3 
ubiquitin ligase complex, which covalently links a chain of ubiquitin residues to α-subunits, targeting 
them to be degraded by the proteasome.  
Under low oxygen conditions, PHD activity is reduced and α-subunits accumulate in the cytoplasm. 
When stable, α-subunits bind to nuclear pore proteins and translocate into the nucleus to form αβ-
heterodimers. These dimers recognize and bind to DNA sequences known as Hypoxia Response 
Elements (HRE) located in the promoter or enhancer region of target genes, whose expression is 
activated (Rocha S, 2007; Heyman SN et al., 2011). To activate the majority of its target genes, HIF 
needs to associate with the transcriptional coactivators p300 or CBP. However this binding is not 
necessary for all HIF target genes, indicating that other transactivating factors or mechanisms are 
possible (Rocha S, 2007).  
There are more than 100 HIF target genes identified in humans. They participate in key pathways in 
cell metabolism and survival, including cell functions necessary for hypoxia adaptation such as 
  
 
50 
 
  
2 INTRODUCTION 
erythropoiesis (EPO), increased glucose intake (Glucose transporter-1), metabolism switch to 
glycosysis (several glycolysis enzymes), lactate metabolism (Lactate dehydrogenase), angiogenesis 
(VEGF), vasodilatation (Inducible Nitric oxide synthase) and free radicals scavenging (HO-1). 
Moreover, there is an increasing evidence of genes whose expression can be repressed by HIF 
(Heyman SN et al., 2011). Recently several miRNAs have been described as HIF targets, including miR-
210 (Rocha S, 2007; Chan YC et al., 2012). 
 
5.1. – Role of Hypoxia Inducible Factor (HIF) in Renal Ischemia/Reperfusion Injury:  
As a key regulator of cells responses to low oxygen tensions, HIF is also an essential transcription 
factor in the renal response to ischemia.  In the last years, several works have evidenced the critical 
protective role of HIF expression against renal I/R.  
Ischemic preconditioning, produced by a transient and mild I/R stimulus, confers kidney protection 
against a subsequent acute ischemic injury by activating several cell signaling pathways, including 
HIF-1α and HIF-2α. Moreover, accumulation of HIF-1α and HIF-2α by pharmacological inhibition of 
PHDs or DMOG administration to mice results in renal protection against ischemia. On the other 
hand, HIF-1α and HIF-2α heterozygous knockdown (KO) mice are more susceptible to I/R injury. (Hill 
P et al., 2008).  
In another experimental approach, conditional inactivation of VHL protein in mice and subsequent 
HIF accumulation resulted in tolerance to renal I/R (Iguchi M et al., 2008). In an allogenic model of 
renal transplant in rats, donor pre-treatment with PHD inhibitor prevented graft injury and increased 
receptor survival (Bernhardt WM et al., 2009).  
As previously mentioned, different α-subunits present non-redundant activities and specific 
expression patterns in each organ and cell type. This is the case of the kidney, in which HIF-2α is 
mainly expressed in erythropoietin producing interstitial fibroblast and peritubular endothelial cells, 
whereas HIF-1α is mainly expressed in tubular epithelial cells (Rosenberg C et al., 2002).   
Consequently, HIF-1α is the main controller of I/R response in proximal tubule cells. Moreover, 
recent studies have pointed out that HIF-1α is essential for proximal tubule cell survival during 
ischemia but also in reperfusion. HIF-1α KO by siRNA administration in vivo aggravates renal I/R 
injury and exacerbates proximal tubule damage (Conde E et al., 2012). In addition, HIF interference 
during reperfusion leads to proliferation/cell death imbalance and impaired tubule repair (Conde et 
al., in preparation).  
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6. – microRNAs:  
miRNAs are small (20-25 nucleotides) non-coding RNAs that have revolutionized our understanding 
of gene post-transcriptional regulation. They are fine tuners of gene expression and more than 50% 
of the genes in mammals are submitted to their control, participating in almost every cellular 
function. Moreover, their deregulation is frequently associated with disease appearance and 
development.  
There have been described approximately 800 miRNAs in humans, a number comparable to the 
known number of transcription factors or other regulatory proteins. Moreover miRNAs show a very 
specific expression patterns that are different among tissues and cell types.  
Their mechanism of action is based on recognition of small sequences in their target mRNAs. This 
feature make possible that one miRNA can regulate hundred of target mRNAs and that one mRNA 
can be regulated by several miRNAs. This dynamic regulation has unveiled them as key regulators of 
a wide range of cellular events, including rapid responses to stress (Krol J et al., 2010b). 
  
6.1. – microRNA Biogenesis:  
miRNAs are mainly transcribed by RNA polymerase II as longer primary transcripts called pri-miRNAs. 
miRNAs genes are often located in non coding DNA regions and they are frequently organized in 
clusters. Clustered miRNAs are transcribed as a single, longer pri-miRNA which generates several 
functional miRNAs by subsequent processing. miRNAs genes can also be found in protein coding 
genes, specially located in introns. In these cases, splicing of the coding mRNAs leads to generation of 
the functional miRNA. As other transcripts produced by RNApolymerase II, pri-miRNAs presents 
5´Cap and 3´Poly-A Tail.  
Pri-miRNAs molecules form imperfect stem-loop structures that can be recognized by a processing 
complex formed by the RNAse III enzyme Drosha and the RNA binding protein (RBP) DGCR8. Stem-
loop double stranded structures of pri-miRNAs are recognized by DGCR8, which guides de positioning 
of Drosha. This catalytic center cleaves pri-miRNAs liberating a hairpin RNA molecule of 70-100 
nucleotides known as pre-miRNA.  
Pre-miRNAs are exported to the cytoplasm by the nuclear export receptor Exportin 5 in a Ran-GTP 
dependent manner. In the cytoplasm pre-miRNAs are further processed by other RNAse III enzyme 
called Dicer. A new cleavage produces a double stranded RNA molecule of 22 nucleotides. One of the 
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strands (the mature miRNA) is transferred to the Argonaute protein to conform the RNA Induced 
Silencing Complex (RISC). The other strand (often called minor, passenger or *strand) is frequently 
degraded. Strand selection mechanism has not been completely elucidated yet. However, it has been 
proposed that the strand with the less stable base-pairing in its 5´end is often chosen as guide strand 
to be loaded in the RISC complex. 
RISC complex is the key effector of miRNA regulation. This complex, joined to other controlling 
factors, is responsible for driving mRNA degradation or translation repression, as will be further 
detailed in following sections (For review Krol J et al.,  2010; Treiber T et al., 2012). 
 
 
Figure 3: MicroRNA biogenesis and function. Modified from Krol J et al., 2010b. 
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6.2. – miRNA Biogenesis Regulation:  
Given the great importance of miRNAs in gene expression regulation and cell function, miRNA 
biogenesis is also submitted to a tight regulation.  
The first control step corresponds to pri-miRNA transcription. Intronic miRNA expression is usually 
governed by the promoter of the host gene. However approximately one third of the intronic 
miRNAs presents additional promoters that allow independent regulation. Intergenic miRNA 
generally present their own promoters, which show all the characteristics of RNA polymerase II 
transcription, such as CpG islands. Clustered miRNAs usually share one promoter for all the encoded 
miRNAs and are transcribed as part of long pri-miRNAs (Treiber T et al., 2012).  
In addition to transcription regulation, pri-miRNA processing can be controlled in RNAse III cleavage 
steps, leading to the accumulation of different intermediate precursors.  
Drosha processing can be regulated by growth factors such as Bone Morphogenic Protein (BMP) or 
Tumor Growth Factor-β (TGF-β), which can stimulate the processing of specific miRNAs (Davis BN et 
al., 2010). Moreover DNA damage-induced p53 pathway can enhance the processing of miRNA 
implicated in tumor suppression functions (Suzuki Hi et al., 2009). In addition, RNA binding proteins 
involved in mRNA splicing and editing can also regulate this step (Trabuchi M et al., 2009; Yang W et 
al., 2006). 
Dicer processing is regulated by Lin-28 in embryonic pluripotent cells. This protein binds to the 
terminal loop of Let-7 family pre-miRNA preventing Dicer cleavage. Lin-28 protein levels are high in 
embryonic stem cells producing repression of let-7 family miRNAs and overexpression of their 
targets, which are involved in pluripotent state maintenance (Viswanathan SR et al., 2008).  
 
6.3. – miRNA Target Recognition and Function:   
Once loaded into the RISC complex, miRNAs recognize their target mRNAs by base-pair 
complementarity. Target sequences are mainly located in the 3´ untranslated region (UTR) of mRNAs. 
However, functional miRNA binding sites can be also found in the 5´ UTR and open reading frame 
regions.  
Nucleotides in positions 2-8, called seed sequence, are essential for pairing with the target mRNA 
and miRNA function. In the case of perfect complementarity of the seed sequence of the miRNA with 
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the target sequence, miRNAs act as a short interfering RNA (siRNA) promoting mRNA cleaving by 
RISC complex. This mechanism is principally found in plants but is very rare in mammals.  
When pairing with target sequences is partially complementary, which is the most frequent 
mechanism in mammals, miRNA regulation is produced by mRNA translation repression or 
degradation. However this degradation process is different and involves recruitment of deadenylase 
complexes that remove or shorten the poly-A tail of the target transcript. Poly-A tail shortening 
induces decapping of the 5´ extreme of the transcript and uncapped mRNAs are rapidly degraded by 
5´ to 3´ exoribonucleases(Figure 4) (For review Krol J et al., 2010b; Treiber T et al., 2012).  
 
 
Figure 4: Mechanisms of miRNA-mediated silencing in animals. Modified from Huntzinger E 
and Izaurralde E, 2011. 
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Translational repression has been proposed to occur in four different ways: 
1) Inhibition of translation initiation.  
2) Inhibition of translation elongation.  
3) Co-translational protein degradation.  
4) Premature termination of translation.  
 
For inhibition of translation initiation increasing evidence suggest that animal miRNAs interfere with 
the function of the eukaryotic translation-initiation complex 4F (eIF4F) and Cytoplasmic poly-A 
Binding Protein (PABPC).  
Post-initiation stage regulation hypothesis are evidenced based on a common observation: miRNAs 
and their targets were associated with polysomes, isolated by sucrose sedimentation gradients. 
These polysomes were sensitive to conditions that inhibit translation, so they were considered to be 
active.  
Several works demonstrated that target mRNAs were translated but no corresponding protein was 
found, probably due to a co-translational degradation of the nascent polypeptide. Other model 
hypothesizes that miRNAs may cause premature dissociation of ribosomes during translation 
(ribosome drop off). Moreover, recent evidence indicates that miRNAs can regulate translation 
independently of iniciation factors through internal ribosome entry sites (IRES) (for review 
Huntzinger E and Izaurralde E, 2011). 
Although contribution rate of mRNA decay and translational repression to miRNA action is a 
controversial topic, it seems clear that target degradation provides a major contribution to silencing 
in mammal cells. In this regard, it has been estimated that mRNA decay is present in 85% of miRNA 
regulation process whereas 15% corresponds to translational repression (Treiber T et al., 2012; 
Huntzinger E and Izaurralde E, 2011).  
Despite these recent advantages, miRNA target recognition and function mechanisms are not 
completely understood yet. In the last years many bioinformatics approaches have been developed 
to facilitate miRNAs target prediction and in silico functional studies. Several target prediction 
programs can be currently found online, such as microcosm (Griffiths-Jones S. 2008) 
(www.ebi.ac.uk/enright-srv/microcosm), Targetscan 4.1 (Friedman RC. et al., 2009) 
(www.targetscan.org/vert_40/) and Pictar I (Krek A. et al., 2005) (www.pictar.mdc-berlin.de). These 
prediction tools principally base their algorithms in sequence complementarity between the 5´seed 
region of the miRNA and the 3´UTR of the target gene.  
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6.4. – Regulation of miRNA function:  
miRNA pathway is strictly controlled not only during miRNA biogenesis but also during miRNA 
function, where several regulation steps can be found.  
In many organisms there are several AGO proteins operating in miRNAs pathways. Recent evidence 
suggest that AGO isoform selection is a step in miRNA function regulation. Mammal cells present 4 
AGO proteins. Although AGO2 is the only one which is able to cleave perfect complementary RNA 
targets, the four isoforms present overlapping functions with weak miRNA sorting preference. 
However, they seem to differ in their ability to repress protein synthesis. Thus differences in AGO 
relative abundance may affect the strength of miRNA repression in particular tissues or cell types. 
Moreover, as different miRNAs could be preferentially loaded in different AGO isoforms, changes in 
cell concentration of individual AGO proteins can also modify the range of miRNAs associated to RISC 
complex.  
Cytoplasmic compartmentalization can control access to binding proteins or concentrate factors 
which participate in the same cellular pathway to facilitate a determinate cell function. In this regard, 
compartmentalization structures such as processing bodies (P-Bodies) and multivesicular bodies 
(MVB) have emerged as potentially relevant elements for miRNA function.  
Translationally repressed mRNAs can accumulate in cytoplasmic structures called P-Bodies. These 
complexes participate in mRNA storage and decay and, consequently, they are enriched in proteins 
involved in translational repression and mRNA deadenylation, decapping and degradation. Several 
studies have demonstrated that RISC complex containing miRNAs and their corresponding target 
genes are located in P-bodies, clearly linking these structures with miRNA function.  However, it is 
important to notice that it P-bodies formation could be also a consequence of miRNA-mediated 
repression rather than an essential element for miRNA function.  
MVB have been identified as contributors to miRNA function and secretion. In their lumen, MVB 
accumulate vesicles that can be secreted or delivered to lysosomes for degradation. Blockade of 
MVB formation inhibits miRNA silencing whereas blocking of MVB turnover stimulates miRNA target 
repression. Moreover, MVB formation blockade leads to impaired small RNA loading in RISC 
complexes, evidencing that MVB play a key role in RISC turnover. 
(For review Krol J et al., 2010b) 
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Selective loading of RISC complex proteins and microRNAs into MVB vesicles to be released as 
exosomes constitutes an essential step in miRNA secretion regulation. This step is essential for 
miRNA function as biomarkers in body fluids, as indicated in previous sections of this work.  
 
6.5. – miRNA decay and turnover:  
Accumulative evidence reveals that different miRNAs present distinct and inherent half-lives that 
could be encoded by their sequence or can be determined after maturation by post-transcriptional 
mechanisms such as uracile and adenosine addition to their 3´end.  
Half-lives of some miRNAs could reach many hours or even days in some organs like the liver or the 
heart (van Rooij E et al., 2007; Gatfield D et al., 2009). However, their ability to regulate rapid cell 
responses to environmental signals makes this slow turnover rate not appropriate for every context. 
Indeed, some miRNAs expressed in retina and involved in darkness adaptation presents half-life of 
approximately 1 hour (Krol J et al., 2010a).  
These interesting data points out that more attention needs to be focused in miRNA turnover 
because miRNA half-life regulation could emerge as potential critical step in miRNA function.  
 
7. – microRNAs in Kidney:  
Due to the relevance of miRNA function and their determinant participation in a wide range of 
processes such as organ development, homeostasis and pathophysiology, miRNA studies in kidney 
development and function has emerged as a field of intense research during the last few years.  
Lack of miRNA activity causes defects in kidney terminal differentiation such as decreased 
proliferation rate, aberrant nephron patterning and delayed terminal differentiation of kidney 
tubules. miR-30 and miR-200 family are two of the most expressed miRNAs in the kidney. Their role 
is essential during kidney development as they strictly regulate the temporal and spatial expression 
pattern of transcription factors involved in pronephron maturation (Wessely O et al., 2010).  
In addition, the expression pattern of several miRNAs changes as kidney development progresses, 
activating or silencing their expression when renal epithelial cells are terminally differentiated and 
cell-fate determination has concluded.  
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Studies based on DICER knockdown in podocytes, juxtaglomerular cells and proximal tubules have 
unveiled the role of miRNAs in kidney function maintenance as well as specific miRNA roles in each 
kidney compartment.   
KO of DICER in glomerulus results in progressive loss of podocyte function leading to proteinuria and 
kidney function impairment and ultimately leading to death (Shi S et al., 2008; Ho J et al., 2008). 
Moreover, DICER deletion in juxtaglomerular cells produces acute loss of this cell type leading to an 
abrupt decrease of renin expression in kidney (Sequeira-Lopez ML et al., 2010).  
All these studies indicate that miRNAs play critical roles in normal renal function and physiology 
maintenance and when altered, may lead to renal diseases.  Specific miRNAs deregulation has been 
linked to renal disease appearance and development. For instance, miR-192 has been identified as a 
critical regulator of collagen production in diabetic nephropathy (Kato M et al.,  2007).  
The clear role of miRNA in kidney function and disease and the ability of miRNAs to regulate rapid 
responses to stress and injury, have unveiled microRNAs as potential key regulator of kidney 
responses to acute damage, such as ischemia/Reperfusion injury.  
  
7.1. – miRNAs in Renal Ischemia/Reperfusion:  
Despite of the intense research in miRNAs in kidney during the last years, publications about 
microRNAs in renal I/R injury are still scarce. However, miRNAs involvement in kidney response to I/R 
was undoubtedly demonstrated by DICER KO experiments in proximal tubular cells. DICER KO mice 
showed normal renal function and proximal tubule structure in basal conditions. However, general 
downregulation of miRNAs conferred a very high protection against I/R reperfusion injury with 
significantly better renal function, less tissue damage, lower tubular apoptosis and improved survival 
compared to wild-type animals (Wei Q et al., 2010).  
Global expression profiling experiments in mice which underwent renal I/R have identified a 
signature of 9 microRNAs (miR-21, miR-20a, miR-146a, miR-199a-3p, miR-214, miR-192, miR-187, 
miR-805, and miR-194) which are differentially expressed in kidney compared to sham controls 
(Godwin JG et al., 2009). Moreover, a more recent work from the same group demonstrates that 
microRNA signature after I/R is different in operated animals compared to sham controls and these 
differences maintain and evolve along time. Their data strongly evidence that differential expression 
of miRNAs after I/R constitute a new biomarker for renal I/R injury (Shapiro MD et al., 2011).  
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A recent study of Liu F. et al. demonstrates that miR-210, a well established miRNA regulated by 
hypoxia, is involved in angiogenesis regulation during renal I/R by activating VEGF and its receptor 
VEGFR2 expression (Liu F. et al., 2012).  
In addition, miRNAs contained in vesicles derived from endothelial progenitors protects renal cells 
from I/R injury. Intravenous injection of microvesicles conferred functional and morphologic 
protection of renal cells by enhancing tubular cell proliferation and reducing apoptosis and leukocyte 
infiltration. These miRNAs also protect kidney from chronic damage progression by inhibiting 
glomerulosclerosis and tubulointestitial fibrosis. Thus, vesicle-derived miRNAs contribute to 
reprogramme resident renal cells to a regenerative program after I/R injury (Cantaluppi V. et al., 
2012).  
The improved knowledge of miRNAs involved in renal I/R injury and recovery could be a key point to 
develop new therapeutic approaches to prevent AKI, reduce chronic diseases derived from acute 
episodes and improve patient outcome. Moreover, identification of microRNas as novel biomarkers 
for AKI could drastically change current clinical practice allowing earlier detection and better patient 
monitoring and management.  
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3 HYPOTHESIS 
AKI is a clinical syndrome characterized by very high mortality rates and hospitalization costs, 
becoming a serious health problem in developed countries. Recent evidence have demonstrated that 
AKI is a complex syndrome which includes both structural and functional kidney injury and whose 
underlying cellular and molecular mechanism are not well understood yet. Ischemic damage is one of 
the most frequent causes of kidney injury and it is present in several clinical contexts such as cardiac 
surgery or renal transplant. I/R injury mainly affect proximal tubule cells provoking cytoskeleton and 
adhesion structures alterations and proximal tubule function impairment. Identification of molecular 
mechanisms underlying kidney ischemic injury and recovery is essential for improving our 
understanding of AKI pathophysiology and identification of new therapeutic targets. 
In addition, current clinical tools for AKI detection and management present important limitations 
which delay AKI diagnosis and treatment with dramatic consequences in patient outcome. Novel 
biomarkers are needed for earlier diagnosis, detect patients at risk and obtain information about AKI 
etiologies and origin. Moreover, these novel biomarkers should be measured in patient samples 
obtained by minimum invasive methods and detected by cost-effective techniques.  
microRNAs are small endogenous RNA molecules which regulate almost every cellular process by 
post-transcriptional mechanisms. They are mediators of long-term processes such as development 
and differentiation, but their dynamic regulation has unveiled them as key mediators of rapid cell 
responses to environmental stimuli and stress, such as ischemia. Hundred of miRNAs have been 
described but these molecules present a precise and highly regulated expression pattern with tissue 
and cell type specific expression profiles.  
Moreover, in the last five years, accumulative evidence has demonstrated that miRNAs not only 
exert their function intracellularly, but they can also be secreted to the extracellular environment. 
This secretion pathway makes possible the detection of miRNAs in extracellular body fluids such as 
serum, where they have demonstrated a great stability. Moreover, changes in serum microRNA 
profiles have been associated to pathologies such as cancer or physiological states such as 
pregnancy. These characteristics have unveiled miRNAs as potential biomarkers for pathology 
diagnosis and monitoring.  
Based on these previous premises, we proposed that miRNAs and their target genes could be key 
regulators of kidney responses to injury, including I/R damage and recovery.  Moreover, due to their 
great cell and tissue specificity, secreted extracellular miRNAs detected in serum could be novel and 
accurate biomarkers of AKI which could contribute to a more precise diagnosis, prognosis and 
management of AKI patients. 
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4 OBJECTIVES 
The principal objective of this work is the study of miRNAs involved in the kidney response to I/R 
injury and their putative role as AKI biomarkers detected in human serum samples.  
To reach this general aim, we propose the following partial objectives:  
1. Identification of miRNAs regulated in response to I/R injury using an in vitro model of 
Hypoxia/Reoxygenation in proximal tubule cells and an in vivo model of renal 
Ischemia/Reperfusion in rat. 
2. Characterization of mechanisms responsible for miRNA expression modulation, including HIF-
1α.  
3. Study of the biological significance of identified miRNAs in proximal tubule cells submitted to 
H/R.  
4. Identification of a serum miRNA profile for AKI diagnosis in human samples.  
5. Validation of selected serum miRNAs in a cohort of ICU patients compared to healthy 
controls and in a cohort of patients undergoing cardiac surgery with CPB. 
6. Study of diagnostic and prognostic values of identified miRNAs, establishing appropriated 
statistical correlations with clinical data.  
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1.- Cell culture and Hypoxia/Reoxygenation (H/R) Protocol: 
NRK-52E cells (ATCC) were cultured in DMEM containing 10% FBS, 2mM glutamine, 100U/ml 
penicillin and 100µg/ml streptomycin (Invitrogen). HK-2 cells (ATCC) were cultured in DMEM/F12 
containing 10% FBS, 1 g/l insulin, 0.55 g/l transferrin, 0.67 mg/l selenium, 2mM glutamine, 100U/ml 
penicillin and 100µg/ml streptomycin (Invitrogen). Both cultures were maintained in a humidified 
atmosphere with 5% CO2 at 37 ºC. 
For H/R protocol, cells were grown until confluence and then they were serum deprived for 24 hours. 
For minimum medium hypoxia (HMM), monolayers were cultured for 6 hours in HBSS (Invitrogen), in 
a low oxygen atmosphere containing 1% O2, 94% N2, 5% CO2 (Air Liquide). For reoxygenation, 
complete medium was added and plates were placed in a regular incubator with 21% O2 (Sáenz-
Morales D et al., 2006). In complete medium hypoxia (HCM), cells were serum starved as described 
above and then submitted to hypoxic atmosphere for 6 hours. Normoxic cells (Nx) were serum 
deprived without nutrient and oxygen tension changes. Serum-starved cells following 6 h in HBSS 
correspond to nutrient depletion control condition (CC) (Figure 5A). 
 
Figure 5: Hypoxia/Reoxygenation and transfection protocols. (A) Schematic representation of H/R protocol 
where changes in nutrients and oxygen tension are indicated for each condition, represented in different 
arrows. (B) Transfection and H/R protocol diagram. Cells are transfected with HIF-1α siRNA, in the case of HK-2 
cells, or pre/anti-miR-127 in NRK-52E cells. 24 hours after transfection, cell cultures undergo H/R protocol as 
described above. 
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Deferoxamine is an iron chelator usually used as hypoxia-mimetic compound to stabilize HIF-1α 
through PHDs inhibition. Deferoxamine is added to culture medium to a final concentration of 300 
µM for 8 hours.  
 
2.- Renal Ischemia/Reperfusion model in Rat: 
Experimental procedures were performed according to the European Community guidelines (EC609), 
Spanish laws (RD 1210/2005) and approved by the Internal Committee for Animal Ethics of Hospital 
Universitario Ramón y Cajal. Male Sprague Dawley rats (180–200 g) were anesthetized with an 
inhaled anaesthesia mixture of 2% isoflurane (Abbott Laboratories Ltd.) and 1 l/min oxygen. Renal I/R 
injury was performed after laparotomy by a 45 min bilateral clamping of renal pedicles. Sham 
operated animals underwent the same surgical procedure without clamping. Animals were sacrificed 
at 0, 24 h, and at 3, 5 and 7 days after reperfusion.  
Blood samples were obtained before sacrifice by punction of the Cava vein. For serum extraction 
tubes were incubated at room temperature for 30 min and then centrifugued at 2500 rpm for 10 
minutes at 4ºC. Kidneys were obtained by dissection of renal pedicles. Half of each kidney was 
directly frozen liquid nitrogen for protein and RNA extraction and the other half was fixed in formalin 
and paraffin embedded for further analysis.  
 
3.- HIF-1α siRNA transfection in vitro: 
HK2 cells at 80-90% of confluence were transfected with 100 nM HIF-1α siRNA (sc-44225, Santa Cruz 
Biotechnologies) or scramble siRNA (sc-37007, Santa Cruz Biotechnologies), using Lipofectamine 
2000 (Invitrogen, Barcelona, Spain) according to manufacturer’s protocol. Transfection is carried out 
for 5 hours and then stopped by adding complete medium to plates. Transfected cells were 
submitted to H/R after 24h of transfection (Figure 5B). Samples were harvested at appropriate times 
in each experiment. 
 
4.- Pre-miR and anti-miR transfection in vitro: 
NRK-52E cells at 80-90% confluence were transfected with 100nM anti-miR-127 (AM17000, Anti-
miRTM miRNA Inhibitor, Life Technologies) y anti-miR-Scramble (Anti-miRTM miRNA Inhibitors-
negative Control #1, Life Technologies) using 1.5l of lipofectamine 2000 in a 24 well plate. Pre-miR-
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127 (AM17100, Pre-miR™ miRNA Precursor Molecule, Life Technologies) and Pre-miR-Scramble 
(AM17110 Pre-miR™ miRNA Precursor Molecules—Negative Control #1, Life Technologies) were 
transfected with a final concentration of 0.1 nM using 0.5 l of lipofectamine 2000 per well. Pre-miR 
and anti-miR final concentrations were chosen after setting experiments, checking miR-127 
expression by qRT-PCR. Treated cells were submitted to H/R protocol after 24 hours of transfection 
(Figure 5B).  
 
5.- Tissue and cell culture RNA extraction and Real-Time PCR:  
Total RNA was isolated from renal tissue and cell cultures with TriPure Isolation Reagent 
(11667165001, Roche Diagnostics) by mechanical lysis and Phenol/Chloroform extraction. Rat kidney 
cortexes were previously manually dissected containing a high proportion of proximal tubules. RNA 
concentration and purity was measured with Nanodrop device (Thermo-Fisher) and RNA integrity 
was checked by agarose gel analysis. 
2 µg of RNA were used to obtain cDNA using Transcriptor First Strand cDNA Synthesis Kit 
(04897030001, Roche Diagnostics). 1l of cDNA was used as template for quantitative PCR reaction 
with SYBR Green (11066420, SYBR Green I Master, Roche Diagnostics). Ribosomal 28s gene was used 
as housekeeping for data normalization. Primers employed were: 28s, forward: 
CAGTACGAATACAGACCG, reverse: GGCAACAACACATCATCAG; Rat KIF3B, forward: 
ATCATACAAACGAGCAGCAG, reverse: GTCTCTTTCAGTTCCAAGGTC; Human KIF3B, forward: 
GCCATTGTAGAGGATCACAG, reverse: CAACAAGCAACTTACTCTCCA.   
 All reactions were carried out in a Light Cycler 480 equipment (Roche) with the following 
temperature protocol: 40 cycles of 95 ºC 10 sec., 60ºC 20 sec. and 72 ºC 20 sec. Quantification 
crossing points (Cq) were calculated with 2nd derivative method (Light Cycler 480 Software 1.5, 
Roche) and data analysis was performed using 2-Cq formula.  
 
6.- microRNA quantification by Taqman Assays: 
Commercially available taqman microRNA assays (Life Technnologies) were used for miRNA 
quantification by real-time PCR in rat kidney tissue and cell cultures, after extraction and 
quantificacion of RNA as previously described.  
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50 ng of total RNA was used for retrotranscription reaction using TaqMan microRNA Reverse 
Transcription Kit (Applied Biosystems). PCR was performed using TaqMan microRNA Assays (Applied 
Biosystems) following manufacturer´s instructions with the following temperature protocol: enzyme 
activation at 95ºC for 10 min.; 40 cycles of 95 ºC 15 sec. and 60ºC for 60 sec. RNU6B was used as 
internal control for data normalization in cell culture studies, whereas ribosomic RNA 5s was 
employed for rat kidney tissue.  
All reactions were carried out in a Light Cycler 480 equipment (Roche). Quantification crossing points 
(Cq) were calculated with 2nd derivative method (Light Cycler 480 Software 1.5, Roche) and data 
analysis was performed using 2-Cq formula.  
 
7.- Protein extraction and Western Blot analysis: 
Cell cultures were harvested in lysis buffer (0.25 M Tris pH=6.8, 6% SDS, 10% glycerol, 20 mM DTT, 
Bromophenol Blue, protease and phosphatase inhibitors) (Sigma-Aldrich). Homogenates were 
mechanically disrupted by syringing and then centrifugued. Precleared supernatants were resolved 
by SDS-PAGE and transferred to nitrocellulose (Hybond-ECL Amersham, GE Healthcare). Primary 
antibodies used: anti-human anti-HIF-1α (90-110 KDa), 1:250 (BD Transduction Laboratories); anti-
KIF3B (85KDa) 1:500 (SC-50456, Santa Cruz Biotechnologies); anti-β-actin (42KDa) 1:1000 (Sigma-
Aldrich). Appropriate horseradish peroxidase-conjugated secondary antibodies (Dako) were used. 
Specific signals were visualized using enhanced chemiluminescence (Amersham Biosciences). 
 
8.- Immunofluorescence: 
NRK-52E cells were grown on coverslips coated with collagen IV (1 g/mL. Sigma-Aldrich). To 
visualize actin cytoskeleton, cells were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton 
X-100, blocked in PBS 1% BSA and stained with Phalloidin-Alexa568 1:40 (Invitrogen), 30 min at room 
temperature. For paxillin and ZO-1 inmunostaining, cells were processed as described above and 
incubated with PBS 1% BSA containing primary antibodies anti-paxillin (Millipore) 1:250 and anti-ZO-
1 (Invitrogen) 1:200, 1 hour at room temperature. Appropriate secondary antibodies anti-mouse 
Alexa488 or anti-rabbit Alexa488 (Invitrogen) were used 1:250 for 1 h at room temperature. After 
washing, samples were mounted with prolong gold antifade reagent with DAPI (Molecular probes). 
Images were obtained with Spectral Confocal Microscope TCS SP5 (Leica Microsystems).  
  
75 
 
  
5 MATERIAL  AND METHODS 
9.- Non receptor-mediated endocytosis assay: 
Pinocytosis capacity of proximal tubule cells was estimated by internalization of fluorescent dextran. 
Dextran-FITC of 70 KDa (SD70S, Sigma-Aldrich) to a final concentration of 1 mg/ml was added to NRK-
52E culture medium 6 hours before sample collection. After incubation, samples were fixed in 4% 
paraformaldehyde and coverslips were mounted using prolong antifade reagent (Invitrogen) with 
DAPI. Images were obtained with Spectral Confocal Microscope Leica TCS SP5.  
Quantification of pinocytosis was performed using NIS-Elements BR Image Software (Nikon). For each 
image, surface of DAPI signal and green signal was estimated in pixels2 and quantification was 
expressed as a Green/DAPI surface ratio. 
 
10.- Identification of Putative HRE Elements: 
For the identification of HIF binding sites within the mir-127 locus we follow the strategy described 
elsewhere (Ortiz-Barahona A et al., 2010). Briefly, we first identified mammal or vertebrate 
PhastCons elements (Siepel A et al., 2005) within the region chr14:100418481- 100419663 containing 
the mir-127 gene. Adjacent PhastCons elements were fused if more than 50% of the sequence in the 
resulting fused region was conserved. We refer to these PhastCons elements located in noncoding 
regions as conserved non coding sequences (CNSs). Then, we identified conserved RCGTG motifs 
within these CNSs. A motif was considered conserved when it was present at least in four mammals 
including human and mouse. Sequences lacking conserved RCGTG motifs were discarded as potential 
HIF-binding sites (HBS). Finally, sequences containing a conserved motif were scored according to a 
position specific scoring matrix (PSSM). Aligments and PhasCons elements were downloaded from 
the UCSC genome browser (Fujita PA et al., 2011) using the February 2009 (hg19) human genome 
assembly. 
 
11.- Chromatin Immunoprecipitation Assay: 
1x107 HK-2 cells were prepared for each immunoprecipitation assay. After serum deprivation or 
hypoxia, crosslinking was performed by adding formaldehyde (1% final concentration). 
1x107 cells were resuspended in Cell Buffer Mix (10 mM HEPES/KOH, pH 7.9; 85 mM KCl; 1 mM EDTA, 
pH 8; 1% NP-40) with 1 mM PMSF and Protein inhibitor Mix (Roche Diagnostics). After centrifugation, 
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pellets were lysed using Nuclear Lysis Buffer (50mM Tris/HCL, pH 7.4; 1% SDS; 0.5% Empigen BB; 
10mM EDTA, pH 8).  
Glass beads were added (Agilent Technologies, Cat: 200069) and sonication was performed in 15 
cycles of 10 sec. with 15% amplitude. After sonication, DNA fragments size was checked by agarose 
gel analysis. Input (5% of the final volume of the lysates) was separated for further determinations. 
Protein concentration of each sample was estimated using the Bradford assay and then adjusted 
using nuclear lysis buffer. Then, each sample was diluted 1:1.5 with Dilution Buffer (20 mM Tris/HCl, 
pH 7.4; 100mM NaCl; 2 mM EDTA, pH 8; 0.5%Triton X-100). Preclearing was performed using 
Sepharose CL-4B beads (Sigma-Aldrich) and incubating for 2 hours at 4ºC. After pre-clearing, 2 µg of 
each antibody (anti HIF-1α  Novus 100-134; anti IgG Millipore 07-690) were added and samples were 
incubated over night at 4 ºC.  
Protein G Agarose beads (Roche Diagnostics) were added to each sample and mixes were incubated 
for 4 hours at 4ºC. After precipitation and washing, DNA was obtained by treatment with Elution 
buffer (0.1M NaHCO3; 1% SDS). Crosslink reversal was performed by adding proteinase K (0.5 ug/uL 
final concentration) and 200 mM NaCl and incubating at 65 ºC over night.  
1 µl of purified DNA was used as template for qPCR reaction, using the following primers for the 
predicted HRE region: Primer pair 1, forward: TCG CTG TGA TCA CTG TCT CC; Reverse: CTG CCA CAC 
CCA TAC TCA GA. Primer Pair 2 Forward: TCT GCT TCC TTC GGG TTA AA ; Reverse: CTA GAG AGG CAC 
GGC ATG AG.  
 
12.- Real Time Monolayer Impedance estimation: 
Real Time Cell Analyzer device (Roche Diagnostics) was used for these experiments. Firstly, 
impedance background was estimated with 100l of appropriate cell culture medium. Then, 30.000 
cells were seeded per well in a final volume of 200l. Culture impedance was measured every minute 
during the first 10 hours, then in 5 minutes-intervals during 24 hours and finally every 10 minutes for 
72 hours. Each condition was studied in triplicates and monolayer impedance was expressed as Cell 
Index, calculated by RTCA Software 1.2.  
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13.- KIF3B 3´UTR cloning and luciferase Assays: 
Rattus norvegicus KIF3B (NM_001106529) complete 3´UTR was inserted downstream of the 
luciferase encoding region of the pGL3-control vector (Promega) using the In-Fusion PCR cloning kit 
(Clontech-Takara) for mRNA instability assays. pGL3-Control vector was digested with XbaI and KIF3B 
3´UTR was amplified from cDNA of NRK-52E cells using specially designed primer pairs which 
generate 15-bp extremes overlapping with pGL3-control (forward: CCG CCC CGA CTC TAG AAG TCC 
CAA GTA CTG GCA TAG CCT TT ; Reverse:  GCC GTG TAA TTC TAG CCC AGC ACC CCT CCC AGG). 
Schemes of the generated constructions as well as used plasmids can be found below.  
 
Figure 6: Schematic representation of expression vectors used in reporter assays experiments. 
(A) Scheme of luciferase-KIF3B 3´UTR vectors S1A and S3B. (B) Empty vector (PGL3 control) used as 
control in luciferase reporter experiments. (C) Renilla luciferase vector used for normalization. 
 
For luciferase reporter assays, 125,000 NRK-52E cells were seeded in 24 well plates and transfection 
was performed at 80% confluence. 1 µg of luciferase plasmid and 0.05 ng of renilla luciferase plasmid 
per well were transfected using 2.5 µl of lipofectamine. Pre-miR-Scramble and Pre-miR-127 were 
simultaneously transfected with a final concentration of 0.1, 1 and 10 nMolar. Each transfection 
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condition was carried in triplicate. Luciferase and renilla luciferase activity was measured after 48 
hours of transfection using Dual-Luciferase Reporter System (Promega) following manufacturer´s 
instructions. Luciferase activity was normalized using renilla luciferase values for each sample.  
 
14.- Human serum samples collection and storage: 
All experimental desings including human samples have been revised and approved by The Clinical 
Investigation Ethical Committee of Ramón y Cajal Hospital. After patients or their legal 
representatives are informed and an informed consent document is signed (See Annex 1) blood 
samples are collected in 8 ml tubes Vacuette Z sep Clot Activator.  
Serum is obtained by centrifugation at 2,500 rpm during 10 minutes. Then it is aliquoted in 250 µl 
samples and stored at -80 ºC according to the quality standards of the Hospital Ramón y Cajal-IRYCIS 
Biobank guidelines (ISO 9001). Each sample is anonymous, is identified by an unmistakable code and 
is associated with a document containing all processing information, such as date and hour of 
freezing, and relevant clinical data for the study. Samples were obtained after appropriate request 
following Biobank procedures.  
 
15.- RNA extraction from serum samples: 
Total RNA is extracted with miRNeasy mini kit (50) (Qiagen, cat no. 217004) using an optimized 
protocol for serum samples. 250 µl aliquots are thawed on ice and spin at 1,000g for 5 minutes at 4 
ºC to remove debris. 200 µl of precleared samples are used for further steps. For each sample, 800 µl 
of phenol master mix is prepared, containing 1 µg of MS2 RNA (Roche, cat. No. 10165948001). For 
data normalization during miRNA detection by qRT-PCR, three synthetic oligonuclotides are also 
added to this master mix: 25 fmol of synthetic C. elegans miR-39 (sequence: 
UCACCGGGUGUAAAUCAGCUUG; Sigma-Aldrich), 25 fmol of miR-54 (Sequence: 
UACCCGUAAUCUUCAUAAUCCGAG; Sigma-Aldrich) (Mitchell PS et al., 2008) and 2x106 copies of 
Spike-In RNA (Unknown sequence; Exiqon).  
750 µl of master mix containing the indicated RNA and housekeepings is added to each 200 µl serum 
sample and mixed by vortex. The following steps (Phenol/Chloroform extraction and column 
purification) were carried out as manufacturer´s instructions, except for RPE buffer washing step, 
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where three repetitions should be done. RNA is eluted from columns adding 50 µl of nuclease free 
water.   
RNA quantity and quality was checked by Agilent Bioanalyzer device using a special kit for small RNA 
studies (Agilent Technologies). RNA is stored at -80 ºC and only one freeze-thaw cycle is produced 
prior to miRNA detection by qRT-PCR.  
The procedure detailed above is also used for cell culture supernatants. After collection, 
supernatants are precleared by centrifugation to remove cellular debris and 200 µl are used for total 
RNA extraction.  
 
16.- microRNA quantification by LNA probes: 
Serum circulating miRNAs were detected and quantified by Real-Time PCR using Universal RT miRNA 
PCR System (Exiqon). 4 µl of the eluted RNA were used as template for universal retrotranscription 
reaction with a final volume of 20 µl. Mixtures were incubated at 42 ºC for 60 minutes and 95 ºC for 
5 minutes and immediately cooled down to 4 ºC. cDNA was diluted 1/11 with nuclease-free sterile 
water and 4 µl were used as template for PCR reaction.  
Real time PCR detection was performed using SYBR Green and specific probes, commercially 
available (Exiqon), for each miRNA of interest. Master Mix preparation and temperature protocol 
were performed following manufacturer´s instructions and temperature protocol was performed as 
follows: enzyme activation at 95ºC for 10 min.; 45 cycles of 95ºC for 15 sec. and 60ºC for 60 sec. All 
reactions were carried out in triplicates in a Light Cycler 480 equipment (Roche) and Cq values were 
calculated with 2nd derivative method (Light Cycler 480 Software 1.5, Roche). miRNA expression 
values are expressed as ΔCq, obtained from the following formula:  
ΔCq= miRNA Cq  - Spike In Cq 
 
17.- microRNA qRT-PCR Array and data analysis: 
Circulating miRNA profiling experiments were carried out using Taqman Low Density Arrays for 
miRNAs (Applied Biosystems). For each sample, total RNA from three different aliquots was extracted 
as detailed above to avoid false results due to aliquot variability or RNA extraction procedure. After 
RNA quantification and quality checking, RNA samples were pooled for further steps.  
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Retrotranscription was performed using Megaplex RT primer pool panel A and B and Taqman miRNA 
retrotranscription kit components (Applied Biosystems) following manufacturer´s indications. Panels 
A and B were used to cover a wider range of miRNAs, which includes a total of 754 assays. 3µl of RNA 
were used as template for this reaction.  
PCR determinations were performed using Taqman Array Human microRNA cards (Applied 
Biosystems). Two cards were run for each sample, corresponding to panel A and B. For each reaction, 
6 µl of retrotranscription product were used as template and PCR reactions were performed 
following manufacturer’s instructions.  
All reactions were carried out in a 7900HT Fast Real-Time PCR System device (Applied Biosystems) 
and raw Cq were obtained using SDS v2.3 software (Applied Biosystems). Baseline and threshold 
settings were carefully optimized and maintained during the whole experiment to assure comparable 
results among the different samples and arrays.  
Raw Cq values were exported and analyzed in Excel (Microsoft). Schematic representation of analysis 
workflow can be found in Figure 7. Firstly, miRNAs not expressed in any sample were eliminated. 
After this step, all values showed as “undetermined” were substituted by 40 as Cq value. Next, ΔCq 
values were calculated (ΔCq= miRNA Cq  - Housekeeping Cq)using as housekeeping control the mean 
of the Cq values of all expressed miRNAs (Cq values <35) (Mestdagh P. et al., 2009). Next, miRNA 
with inconsistent ΔCq values between control samples (ΔΔCq>1) were also excluded from the study. 
 
 
 
 
 
 
 
Figure 7: qRT-PCR array 
analysis workflow: 
Schematic representation 
of raw data management 
and miRNA selection 
steps.  
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After these initial selection steps, based on technical criteria, fold changes were calculated using 2 -
Cq method. Downregulated miRNAs values (Folds<1) were transformed into negative values 
applying the following equation: transformed fold value= -1/fold value. After application of statistical 
tests, only miRNAs showing statistically significant changes over ±2 folds were taken into account for 
further steps.  
For final selection, miRNAs showing most prominent and significant changes were submitted to 
functional analysis based on their predicted target genes. For each miRNA, potential targets were 
downloaded from Targetscan Human 5.1 database (http://www.targetscan.org/vert_50/; Friedman 
RC. et al., 2009). Target gene list were then analyzed using the online Bioinformatic Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/tools.jsp; 
Huang da W. et al., 2009). Functional annotation tool was used with human genome background and 
default settings. Target genes were classified into functional categories of Gene Ontology (GO) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Statistical analysis was performed to 
indicate whose functional categories are enriched in the target gene list compared to their relative 
abundance in the whole human genome. Only miRNA whose target genes were enriched in 
functional categories relevant for our study context were taken into account for selection of the final 
panel of miRNAs. 
 
18.- Patient Cohorts: 
18.1. Serum circulating miRNA profiling experiments: 
For this experiment, 10 healthy subjects and 4 AKI patients were included, divided into the following 
groups: 
o Two pools (n=5 individual each) of healthy controls: Volunteers without pathologies or 
pharmacological treatment. Distribution of individuals between both pools was 
performed matching age mean, proportion of men/women and proportion of 
smokers/non smokers.  
o AKI patients with different etiologies were selected from AKI patient collection reference 
AD4-FRA, stored in Ramon y Cajal Hospital-IRYCIS Biobank, including:  
 2 patients with Ischemic AKI. For each one, two samples were used: one at the 
day of diagnosis (Day 0) and other when renal function is recovered (Days 7-10).  
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 1 patient withToxic AKI. Two samples were used: one at the day of diagnosis (Day 
0) and other when renal function is recovered (2 Months). 
 1 Patient with Septic AKI. Only sample at the day of diagnosis was included.  
 
18.2. ICU AKI Patients: 
For this experiment healthy controls and ICU patients with AKI were obtained from collections AD-5-
BCS and AD1-FMO respectively, stored in Ramon y Cajal Hospital-IRYCIS Biobank. 55 individual were 
analyzed, divided in the following groups:  
o 20 Healthy controls without pathologies. 
o 35 ICU patients with AKI, including: 
  19 patients presenting intrinsic AKI (ATN). 
  16 patients with pre-renal AKI.  
In this cohort, AKI was diagnosed using AKIN criteria. For this purpose, only changes in serum 
creatinine were taken into account. Patients were considered having pre-renal azotemia when renal 
function returns to baseline serum creatinine after adequate treatment in least than 72 hours. For 
each patient, we have analyzed serum samples collected at day 0 (Diagnosis), day 1, day 2, day 3 and 
day 7 of evolution, when available.  
 
18.3. Cardiac Surgery with Cardiopulmonary Bypass Patients: 
For these experiments, we have collected a cohort of adult and pediatric patients who underwent 
cardiac surgery with CPB. This patient sample collection is stored in Ramon y Cajal Hospital-IRYCIS 
Biobank with reference AD3-CEC.We have analyzed 39 patients organized in the following groups:  
o IA:   10 adult patients with 0-2 points in Thakar system.  
o IB:   10 pediatric naïve patients operated with CPB. 
o II:  15 adult patients with altered baseline renal function and > 5 points in Thakar             
system.  
o III:   4 adult patients with normal renal function and > 5 points in Thakar system.  
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Thakar system graded the preoperative risk of AKI development after cardiac surgery (Thakar CV et 
al., 2005). In this set of patients, AKI was diagnosed using RIFLE, AKIN and creatinine kinetics criteria 
independently. As in previous cohorts, only changes in sCr were considered. For each patient, we 
have analyzed serum samples at different time-points: Basal (before surgery), Immediate post-
surgery (IPS), 24, 48, 72 hours and 7 days after surgery.  
 
19.- Statistical Analysis: 
Data are presented as mean±s.e.m in case of in vitro and in vivo experimental model data. Median 
and first and third quartiles are presented for patient miRNA expression data.   
For experimental models data and patient results, statistical analyses were performed as follows: 
Shapiro-Wilk test was first performed to confirm or reject normal distribution. After the Levene test 
for homogeneity of variance, T-Test and ANOVA with post hoc Bonferroni correction were used for 
normal samples. For non-normal distributed data, the following non parametric analysis were used: 
Kruskal–Wallis test for group comparison and for intergroup differences post hoc Mann–Whitney U-
tests. P<0.05 was considered significant. Spearman Rho correlation coefficient was used for 
correlation studies between numerical variables.  
Hierarchical clustering analysis using squared Euclidean distance method was employed for patient 
group classification in massive screening analysis. Receiver-Operator Characteristic (ROC) curve test 
was performed to evaluate sensitivity and specificity of miRNAs as AKI biomarkers. Statistical 
analyses were performed using Statistical Package for the Social Sciences (SPSS) software version 
19.0.
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1. - miR-127 is induced in response to H/R and I/R: 
As miRNAs are dynamic regulators of cell responses to environmental stimuli and stress (Krol J et al.,  
2010), we hypothesized that  the regulation of the expression of these molecules could be involved 
in the proximal tubule response to I/R injury. For this purpose, previous work of our lab performed a 
massive screening experiment, using hybridization microarrays, in rat proximal tubule cells (NRK-52E) 
submitted to H/R. As it is detailed in material and methods section, H/R protocol closely mimics the 
stimuli to which proximal tubule cells are exposed during I/R in vivo. This massive screening 
experiment led to a set of miRNAs that modulated their expression during hypoxia and 
reoxygenation (Table 2). 
 
TABLE 2: Differentially expressed miRNAs in NRK-52E cells submitted to H/R.  
 
 
 
 
 
 
 
 
In this work, we validated these initial microarray data by real time PCR (qRT-PCR) using taqman 
assays. Data are expressed as fold change, calculated by 2 –ΔΔCt method comparing each sample to 
Normoxia (Nx). From the set of miRNAs which significantly modulate their expression under H/R, rno-
miR-127 was the most consistent and significantly modulated miRNA in NRK-52E cells, showing an 
increased expression during minimum medium hypoxia (mimicking ischemia) and at 1 hour of 
reperfusion (Figure 8A). 
In the next step, we wanted to assess if miR-127 modulation was conserved among species. Thus we 
studied the expression of the human homolog of rno-miR-127 (hsa-miR-127-3p) in the human 
proximal tubule cell line HK-2 submitted to H/R protocol. qRT-PCR data demonstrated that hsa-miR-
Control vs Hypoxia Hypoxia vs Reoxygenation 
miRNA Fold change miRNA Fold change 
rno-miR-101a 1 rno-miR-101a 2,63 
rno-miR-127 1,16 rno-miR-127 2,46 
rno-miR-129* 1 rno-miR-129* 2,13 
rno-miR-154 1 rno-miR-154 8,03 
rno-miR-28 1,27 rno-miR-28 1,90 
rno-miR-376b 1,33 rno-miR-376b 6,70 
rno-miR-223 1 rno-miR-223 -1,91 
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127-3p is also induced in human cells, but showing a different expression pattern. In this case, we 
found increased expression during complete medium hypoxia and along reoxygenation (Figure 8A, 
lower panel). Differential regulation of miR-127 between species could be underlying the different 
expression pattern between human and rat, as we will discuss later.  
 
Figure 8: miR-127 is modulated in response to Hypoxia/Reoxygenation in vitro and during 
Ischemia/Reperfusion in vivo. (A) rno-miR-127 modulation in rat proximal tubule cells NRK-52E 
(Upper panel) and human proximal tubule cells HK-2 (Lower panel) submitted to H/R protocol. 
Data are presented as mean ± s.e.m. of five independent experiments. Asterisks indicate 
statistical significance comparing each sample with Normoxia (Nx) (P<0.05). (B) rno-miR-127 
modulation in rat kidney in response to ischemia/reperfusion (I/R). Data are presented as mean ± 
s.e.m. of at least five animals per condition. Asterisks indicate statistical significance (P<0.05) 
comparing each experimental group to Sham condition.  
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In addition, we studied whether this induction could be also observed in our in vivo model of renal 
I/R in rat. In this model, proximal tubule cell damage is observed during reperfusion followed by 
renal dysfunction. As can be observed in figure 8B, rno-miR-127 is induced after ischemia and at 24 
hours of reperfusion, time-point when tissue and renal function damage is maximal (Conde E et al, 
2012).  
Taken together, these data indicate that miR-127 is modulated in proximal tubule cells and renal 
tissue in response to H/R and I/R, respectively.  
 
2. - hsa-miR-127 is regulated during H/R by HIF-1α: 
Once we have observed that miR-127 is modulated during H/R and I/R, we went further into miR-127 
regulation. As indicated before, HIF is the key regulator of transcriptional responses to hypoxia 
(Rocha S., 2007) and HIF-1α is the main isoform expressed in kidney proximal tubule cells. Based on 
this evidence, we hypothesized that this subunit could be a regulator of miR-127 induction in our in 
vitro system.  
To assess this issue, we performed HIF-1α knockdown experiments by siRNA transfection in HK-2 
cells, since HIF-1α knockdown did not work in NRK-52E cells. Previous work of our lab demonstrated 
that in our in vitro model, HIF-1α is expressed not only during hypoxia, but also at several time points 
during reperfusion, showing a biphasic induction pattern (Figure 9A) (Conde E. et al 2012).  
We studied hsa-miR-127 expression by qRT-PCR in HK-2 cells transfected with specific HIF-1α siRNA 
and scramble control. Data are presented as fold change values, using scramble normoxia as 
reference. microRNA expression values are compared between scramble and siRNA for each 
condition. As shown in Figure 9B, HIF-1α interference successfully prevented hsa-miR-127 induction 
in complete medium hypoxia (Hyp CM) and 1 hour of reperfusion. HIF-1α knockdown control 
western blot demonstrating significant HIF-1α inhibition is shown in Figure 9C.  
These interference results demonstrate that HIF-1α is a regulator of miR-127-3p expression in HK-2 
cells during H/R.  
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Figure 9: HIF-1α regulates miR-127-3p in HK-2 cells in response to Hypoxia/Reoxygenation. (A) HIF-1α 
stabilization in HK-2 cells during H/R protocol was estimated by western blot using β-tubulin as loading control 
(lower panel). Representative image from five independent experiments is shown. (B) hsa-miR-127-3p 
expression in HK-2 cells transfected with scramble (White bars) or HIF-1α siRNA (Black bars). microRNA 
expression was determined by quantitative PCR and fold values were obtained comparing each sample to 
Normoxia scramble (Nx). Data are presented as mean ± s.e.m. of five independent experiments. Asterisks 
indicate statistical significance (P0.05) comparing scramble to siRNA values in each condition. (C) Interference 
efficiency was estimated by HIF-1α detection by western blot. Upper panel shows HIF-1α stabilization in 
scramble transfected cells submitted to H/R whereas lower panel indicates HIF-1α protein levels in siRNA 
transfected cells. β-tubulin was used as loading control. Deferoxamine was used as a positive control for HIF-1α 
stabilization. Representative western blot image from five experiments is shown.  
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Trying to characterize miR-127-3p regulation by HIF-1α, in the next step, we studied if this regulation 
tood place by direct binding of this transcription factor to putative HRE elements located close to 
miR-127-3p sequence.  
First, we performed, by bioinformatics approaches, a HRE prediction study in the genomic region 
where hsa-miR-127-3p gene is located. This prediction, based on sequence alignment, conservation 
and a position scoring matrix data, identified a potential functional HRE downstream miR-127-3p 
sequence (Figure 10). This element was conserved among vertebrates and was located in a CpG 
island, making it a good candidate for miR-127 regulation.  
 
 
Figure 10: miR-127 gene DNA region presents a putative Hypoxia Response Element 
(HRE). Bioinformatics sequence alignment and conservation studies detected a consensus 
HRE sequence (CACGT) downstream miR-127 coding region. Alignment map (upper part) 
shows miR-127 gene and HRE element location into human genomic DNA. Sequence 
scheme (lower part) indicates that this HRE element (marked in red) is conserved among 
mammals and several vertebrate species. 
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To demonstrate whether HIF-1α directly binds to this predicted HRE element, we performed 
Chromatin Immunoprecipitation (ChIP) assays in HK-2 cells submitted to H/R. In this method, protein 
and chromatin crosslinking is performed and HIF-1α is precipitated using a specific antibody.  The 
precipitation of the transcription factor draws the chromatin to which the factor is bound to manage 
its transcriptional regulation. After precipitation, crosslinking is reversed and the chromatin is 
isolated. Then, the region of interest can be studied by qRT-PCR using specific primers. Results are 
represented as percentage of input (samples where any precipitation or antibody treatment has 
been done) and IgG antibody is used as technical negative control.  
Two primer pairs were designed to study the predicted HRE element (Figure 11A), but as can be 
observed in figure 11B, after HIF-1α antibody was used for precipitation, none of the studied 
sequences increased their relative concentration during hypoxia, compared to normoxia condition. 
These data indicated that HIF-1α does not directly bind to the predicted HRE element.  
 
Figure 11: HIF-1α does not directly bind to the predicted HRE element. Chromatin immunoprecipitation 
assays were performed and target sequence containing the predicted HRE element was studied by qRT-PCR 
using two different primer pairs (A) Primer pair aligment with genomic DNA. miR-127-3p mature sequence 
is marked in bold and predicted HRE element is highlighted in blue. (B) qRT-PCR data are presented as 
mean±SEM of percentage of input of two independent experiments. IgG antibody was used as negative 
control for precipitation.  
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Taken together, these data demonstrate that HIF-1α is a regulator of hsa-miR-127 in our in vitro 
system. However, the functional HRE for HIF-1α binding could not be successfully identified in our 
study. This could indicate that the active HRE elements involved in miR-127-3p regulation could be 
located far from the miRNA sequence or that HIF-1α transcription regulation could be indirect, as it 
will be further discussed.  
 
3. - rno-miR-127 modulation leads to changes in cell adhesion and cytoskeleton structure: 
After studying the modulation and regulation of miR-127 in our system, we wanted to assess the 
biological significance of induction of this miRNA during H/R. Previous work of our lab demonstrated 
that H/R injury leads to proximal tubule cell adhesion alterations by cytoskeleton disorganization and 
redistribution and disassembly of adhesion complexes (Sáenz-Morales D et al., 2006). Based on these 
data, we hypothesized whether miR-127 modulation could regulate cell adhesion during H/R.  
Firstly, we performed adhesion assays in NRK-52E cells where miR-127 expression is modulated by 
transfection of Pre-miR-127, Anti-miR-127 and their corresponding scramble controls (Pre-miR-sc and 
Anti-miR-sc). Cell adhesion was estimated by monolayer impedance, measured by Real Time Cell 
Analyzer (RTCA) device.  
RTCA plates contain 16 cell culture wells whose bottom is covered by interdigitated micro-electrodes. 
The presence of cells on top of the electrodes alters the local ionic environment at the 
electrode/solution interface, leading to an increase in the electrode impedance. Thus, the more cells 
are attached on the wells, the higher electrode impedance. In addition, impedance depends on the 
cell number as well as the quality of the cell interaction with the electrodes. Thus, increased cell 
adhesion or spreading will lead to a larger change in electrode impedance. Therefore, electrode 
impedance can be used to monitor cell number, morphology, and adhesion degree. 
Impedance is expressed as arbitrary Cell Index (CI) units, calculated by RTCA software. The CI at each 
time point is defined as (Rn-Rb)/15; where Rn is the cell-electrode impedance of the well when it 
contains cells and Rb is the background impedance of the well with the media alone. 
Adhesion assays were performed under normoxic and H/R conditions. For normoxic measurement, 
cells were seeded in RTCA plates 24 hours after transfection and real time measurement of cell 
culture impedance was performed. For hypoxia condition transfected NRK-52E cells were submitted 
to serum starvation and hypoxia. Immediately after hypoxic treatment, they were detached and 
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seeded in RTCA plates to allow impedance measurement during reperfusion. Each transfection 
condition was measured in triplicate. 
As can be observed in Figure 12, rno-miR-127 overexpression by pre-miR transfection increases 
monolayer impedance under normoxic conditions and during reperfusion.  
 
 
Figure 12: miR-127 overexpression promotes cell adhesion during Normoxia and Reoxygenation. NRK-
52E cells were transfected with pre-miR-127, anti-miR-127 and their respective scramble control. 
Adhesion was estimated by measuring monolayer impedance with RTCA device under Nomoxic and 
Reoxygention conditions. Each transfection condition was measured in triplicate and cell index is 
presented as mean±s.e.m. Representative images from 3 independent experiments are shown. 
 
Based on these initial data, we wanted to confirm whether an increase in cell impedance was 
associated to cell adhesion promotion by miR-127. To asses this issue, we studied, by 
immunofluorescence staining, proximal tubule epithelial cell-matrix and cell-cell adhesion structures.  
Ischemic injury leads to actin cytoskeleton remodeling and stress fibers formation. Actin cytoskeleton 
disorganization contributes to loss of cell polarity and disassembly of adhesion structures such as 
Focal Adhesion complexes (FAC) (Sáenz-Morales D et al., 2006). As indicated in previous sections of 
this work, these complexes are composed by transmembrane proteins called Integrins, α-actin and 
intermediary proteins such as Paxillin and are responsible for cell adhesion to extracellular matrix. 
We performed fluorescence staining for actin (red) and immunofluorescence for Paxillin (green) in 
NRK-52E cells transfected with pre/Anti-miR-127 and submitted to H/R. As can be observed in Figure 
13, miR-127 overexpression prevents actin cytoskeleton disorganization and promotes actin-paxillin 
co-localization (Yellow colour in marked circles), indicating FAC correct assembly. Moreover, miR-127 
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blockade by anti-miR aggravates cytoskeleton and adhesion structures disorganization caused by 
hypoxia.  
 
Figure 13: miR-127 overexpression protects actin cytoskeleton organization and focal adhesion 
complexes assembly during H/R: Fluorescence staining and immunofluorescence to detect actin 
cytoskeleton organization (Red) and paxillin localization (Green) was performed in transfected NRK-52E 
cells. Representative confocal microscopy images from three experiments are shown. Co-localization 
paxilin/actin, as indication of FAC assembly, is marked by circles. Magnification 400X.  
 
On the other hand, tight junctions (TJ) are essential for epithelial barrier impermeability and they are 
disrupted by H/R injury, as we previously demonstrated (Sáenz-Morales D et al., 2006).TJ are 
composed by a network of sealing strands formed by transmembrane proteins, mainly claudins and 
occludins, embedded in both plasma membranes. These proteins associate with different peripheral 
membrane proteins responsible for anchoring TJ strands to the actin cytoskeleton, including the 
zonula occludens-1 protein (ZO-1). 
  
 
96 
 
  
6 RESULTS 
We investigated the effects of rno-miR-127 modulation in TJ integrity by immunofluorescence of ZO-
1. In normal conditions, ZO-1 presents a continuous staining along the plasma membrane of proximal 
tubule cells. However, this continuous distribution is lost during H/R. Anti-miR transfection clearly 
enhances hypoxic damage increasing ZO-1 redistribution from the membrane to the cytoplasm, 
resulting in a discontinuous signal along the membrane and leading to the appearance of gaps among 
epithelial cells (Figure 14).  
 
Figure 14: miR-127 overexpression in vitro abrogates tight junction disruption during H/R. NRK-52E cells 
were transfected with pre-miR-127, anti-miR-127 and their respective scramble controls. 24 hours after 
transfection, they underwent H/R protocol. ZO-1 immunofluorescence was used to study tight junction 
integrity. Representative confocal microscopy images are presented from three independent experiments. ZO-
1 redistribution from plasma membrane as indication of TJ disruption is marked by arrows. Magnification 400X.  
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In summary, all these data demonstrate that rno-miR-127 induction promotes maintenance of 
proximal tubule structure and function during H/R by preventing cell adhesion structures alterations 
and maintaining cell monolayer integrity.  
 
4. - Kinesin Family Member 3B (KIF3B) is a rno-miR-127 target in rat proximal tubule cells 
during H/R: 
To go further into the biological significance of rno-miR-127 induction, we performed a 
bioinformatics target prediction study using the databases available online: microcosm (Griffiths-
Jones S. 2008) (www.ebi.ac.uk/enright-srv/microcosm), Targetscan 4.1 (Friedman RC. et al., 2009) 
(www.targetscan.org/vert_40/) and Pictar I (Krek A. et al., 2005) (www.pictar.mdc-berlin.de).  
These target prediction programs base their algorithms in sequence complementarity between the 
5´seed region of the miRNA (bases 2 to 8) and the 3´UTR of the target gene. To improve the 
likelihood of target recognition other parameters are taken into account for prediction, such as the 
target site conservation among species, the thermodynamic stability of the mRNA/miRNA duplex and 
the absence of secondary structures surrounding the miRNA binding site.  
However, in addition to these common characteristics, there are some differences among the several 
approaches. Both TargetScan and Pictar I take into account evolutionary conservation of target sites 
for their predictions. However, Pictar I allows both perfect and imperfect seed complementarity, 
always avoiding G-U pairing. TargetScan includes a “context score” including features such as local A-
U content and target site position in the UTR. microCosm is the less restrictive algorithm because it 
does not require exact seed complementarity and their predictions include G-U pairing (van Rooij E. 
2011).  
Due to these differences in prediction algorithms, results from the three databases were compared 
and only those genes included in at least two databases were taken into account. Combining results 
from several databases to look for overlapping predictions has been demonstrated as the strategy 
with the highest sensitivity when compared with experimentally validated data sets (van Rooij E. 
2011). We finally chose KIF3B and MAPK-4 for further studies due to their potential biological 
significance in our system since KIF3B is involved in cellular trafficking (Reed AA. et al., 2010), and 
MAPK-4 has been involved in microtubule cytoskeleton organization (Beck M et al., 2010). However, 
MAPK-4 did not finally behave as a real target of miR-127 in our system (data not shown) and we 
focus our studies in KIF3B. 
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Firstly, we wanted to assess if this protein was modulated in proximal tubule cells during H/R. For 
this purpose, we studied mRNA and protein levels of KIF3B by qRT-PCR and western blot respectively 
in NRK-52E cells under H/R. KIF3B mRNA levels were reduced during minimum medium hypoxia and 
1 hour of reperfusion in NRK-52E cells, time-points when miR-127 is induced. Similar expression 
pattern could be observed at protein level (Figure 15).  
 
Figure 15: KIF3B is modulated in NRK-52E cells submitted to H/R. KIF3B mRNA and protein levels were 
estimated in NRK-52E cells submitted to H/R. mRNA levels were determined by quantitative PCR. Fold changes 
were calculated using Normoxia (Nx) as basal condition. Data are presented as mean ± s.e.m. of five 
independent experiments and asterisks indicate statistical significance (P0.05) when each sample is compared 
to normoxia. KIF3B protein levels were estimated by western blot using actin as loading control. Representative 
blot from five different experiments is shown. 
 
Moreover, we performed Pre/Anti-miR transfection experiments to determine whether modulation 
of miR-127 could regulate KIF3B expression. Although significant changes were not found for mRNA 
studies, since miRNAs in animal cells could work through blocking mRNA translation, miR-127 
overexpression and inhibition modulate KIF3B protein (Figure 16). KIF3B levels are decreased when 
miR-127 is overexpressed, particularly during Control Condition (CC) and minimum medium hypoxia 
(Hyp MM). These results identify for the first time KIF3B as a real target of miR-127 in our system. 
To further confirm KIF3B modulation by miR-127, KIF3B 3´UTR was cloned into luciferase vectors and 
mRNA destabilization assays were carried out. For this experimental approach, luciferase gene 
expression is driven by SV-40 promoter and KIF3B 3´UTR is cloned after luciferase gene (Figure 6, 
Material and Methods section). This vector configuration produces high expression levels of 
luciferase in basal conditions. However, after miRNA overexpression by pre-miR transfection, 
luciferase expression levels will be reduced by mRNA degradation or translation inhibition if the 
miRNA binds to the cloned UTR.  
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Figure 16: KIF3B is modulated in response to miR-127 overexpression and inhibition. Study of KIF3B mRNA 
and protein levels in NRK-52E cells transfected with pre/Anti-miR-127. KIF3B mRNA was estimated by qRT-PCR 
in cells treated with pre-miR-127 (left panel) and anti-miR-127 (Right panel). Fold change were calculated using 
Nx Scramble as reference condition. KIF3B protein levels were assessed by western blotting using actin as 
loading control. Illustrative blots from five independent experiments are shown. 
 
Two independent constructions, named as S1A and S3B, were generated to avoid possible side-
effects due to mutations undetected by sequencing or other unpredictable effects of cloning 
procedure (Figure 6, Material and Methods section). Both UTR constructions and pGL3 Control 
empty vector were transfected with different concentrations of Pre-miR-127 in NRK-52E cells. Renilla 
luciferase activity was used for normalization control.  
Data are shown as percentage of luciferase activity reduction by Pre-miR-127 in comparison to 
scramble control (Scramble=100). miR-127 overexpression significantly reduces luciferase activity in 
both UTR vectors in a dose-dependent manner, demonstrating that this miRNA directly regulates 
KIF3B expression through recognition of its 3´UTR. Therefore, KIF3B is a real target of miR-127 in our 
system (Figure 17).   
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Figure 17: KIF3B is a real target of miR-127 in NRK-52E cells. Luciferase assays of KIF3B 3´UTR 
vectors, named as S1A and S3B, and empty vector (pGL3-control). Luciferase activity percentage is 
represented, using renilla activity as normalization control. Asterisks indicate statistical significance 
between Pre-miR-scramble and Pre-miR-127 transfected cells in each condition (P<0.05). 
 
Finally, as KIF3B has been involved in endocytosis and transport along microtubules in proximal 
tubule cells (Reed AA. et al., 2010), we wanted to study if modulation of miR-127 could affect cell 
trafficking in our system. For this purpose, we performed non-receptor mediated endocytosis assays 
in NRK-52E cells transfected with Pre/Anti-miR-127, mimicking the function of substance 
reabsorption by proximal tubule cells in vivo. In these assays, Dextran-FITC is added to culture 
medium and incubated for 6 hours. After this period, cells are fixed and nuclei are stained with DAPI.  
As can be observed in Figure 18A, miR-127 overexpression significantly reduced endocytosis activity, 
whereas miR-127 blockade markedly rose Dextran-FITC internalization. Quantification of Dextran-
FITC internalization confirming these results is shown in Figure 18B. For each image, surface of DAPI 
signal and green signal were estimated in pixels2 and quantification was expressed as a Green/DAPI 
surface ratio. 
These results demonstrate that KIF3B is a target gene for rno-miR-127 in NRK-52E cells during H/R, 
both might be regulating proximal tubule cell trafficking, with relevant implications for renal 
function.  
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Figure 18: miR-127 regulates trafficking in rat proximal tubule cells in response to H/R.  (A) Non receptor-
mediated endocytosis assays in NRK-52E cells transfected with pre-miR-127, anti-miR-127 and their respective 
scramble controls. Dextran-FITC of 70 KDa was added to culture medium and nuclei were stained with DAPI. 
Representative confocal images from five independent experiments are shown. (B) Quantification of previous 
images expressed as green signal surface/ blue signal surface ratio, each signal estimated in pixels
2
. 
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5. - Extracellular miRNAs can be detected in supernatants from proximal tubule cell 
cultures: 
As mentioned in previous sections, accumulating evidence during the last five years has 
demonstrated that miRNAs are present not only inside the cell, but also can be secreted to the 
extracellular environment, where they exert cell communication and regulatory functions that have 
not been completely elucidated yet. Based on this evidence, we hypothesized whether proximal 
tubule cells could secrete miRNAs to the extracellular environment and if these miRNAs could reflect 
the intracellular miRNA expression events that we have previously observed, becoming biomarkers 
of cell injury.  
To answer this question, we studied hsa-miR-127-3p expression in supernatants from HK-2 cells 
submitted to H/R. For these experiments, total RNA was extracted following the same procedure 
detailed for serum samples. Before extraction, supernatants were submitted to preclearing by 
centrifugation to eliminate cellular debris and avoid false positive results. miR-127-3p was quantified 
by qRT-PCR using Taqman probes. 
As can be observed in Figure 19 miR-127 was successfully detected in supernatants from human 
proximal tubule cells submitted to H/R, showing a similar expression pattern as observed in previous 
in vitro experiments. These preliminary data clearly demonstrated that proximal tubule cells secrete 
miRNAs to the extracellular environment, thus these molecules can be biomarkers of proximal tubule 
responses to several stimuli, including I/R.  
 
Figure 19: miR-127 is secreted to HK-2 cell cultures supernatants. miR-127 was detected by qRT-
PCR in supernatants from HK-2 cultures. Fold changes were calculated using Normoxia (Nx) as 
reference condition. Data are presented as mean ± s.e.m. of three independent experiments. 
Asterisks indicate statistical significance comparing each sample with Normoxia (P<0.05). 
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6. - Serum miRNAs profile is different between healthy people and AKI patients: 
Based on this previous evidence, we hypothesized whether miRNAs detected in peripheral body 
fluids could reflect kidney responses to injury or renal pathologies such as AKI.  
To perform these experiments, both serum and urine were considered since these peripheral fluids 
are easily and routinely obtained in clinical practice. However, we finally chose serum for further 
studies because anuria is a common feature in AKI, especially in critically ill patients, making difficult 
to perform studies in this fluid.  
To identify seum miRNAs diferentially expressed between healthy people and AKI patients, we 
performed a massive screening experiment using qRT-PCR arrays. For this initial experiment, two 
pool of healthy people (n=5 each) and 4 AKI patients were included. In AKI patients, two samples 
were used, one obtained at time of diagnosis (Day 0) and other at resolution, when serum creatinine 
values have returned to normal.  Clinical settings for these patients can be found in detail in Table 3. 
 
Table 3: Clinical settings of AKI patients and healthy control pools used in the massive screening 
experiment. 
 
Raw Cp data was obtained and hierarchical clustering analysis was performed using all the expressed 
miRNAs. As can be observed in Figure 20, serum miRNA profile successfully classifies the samples 
included in the experiment. AKI patients cluster apart from healthy controls and toxic recovered 
sample. Ischemic patients samples are grouped together resulting in two small groups: day 0 
(Diagnosis) and day of recovery. Samples from recovered patients are not classified in the healthy 
 Age Gender 
AKI 
Etiologies 
AKIN 
Grade 
Serum Creatinine 
(mg/dl) 
Diagnosis Recovery 
Healthy Control       
Pool 1 (n=5) 32.8 ± 5.8 2 Men/3 Women N/A N/A 0.85 ± 0.12 N/A 
Pool 2 (n=5) 36.6 ±8.6 3 Men/2 Women N/A N/A 0.74 ± 0.13 N/A 
AKI Patients       
1 41 Man Ischemic 3 13 2.42 
2 45 Woman Toxic 3 4.81 0.68 
3 63 Woman Septic 3 1.53 - 
4 47 Man Ischemic 2 5.01 1.03 
N/A: Not Applicable 
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control pool group, probably indicating that, although creatinine levels are normalized and AKI is 
clinically resolved, there could be an underlying cellular and tissue damage that modifies miRNA 
expression. By contrast, saple from toxic recovered AKI appears similar to control pools, probably 
due to the fact that this sample was obtained 2 months after diagnosis. On the other hand, toxic and 
septic AKI samples show a great distance between them and with ischemic AKI samples. This feature 
reflects the great biological and molecular differences underlying the different AKI etiologies.  
 
Figure 20: Serum miRNA profile discriminates AKI patients from healthy controls. Hierarchical clustering 
analysis was performed using raw Cp data from all miRNAs expressed in at least one sample. Obtained 
dendrogram showing the arrangement of clusters derived from the analysis is shown.  
 
Taken together, all these data demonstrated that serum miRNAs profile can differentiate between 
AKI patients and healthy people. Moreover, serum miRNAs seems to distinguish AKI etiologies and 
different recovery degrees over time.  
After this initial study, raw expression data was normalized and fold expression changes were 
calculated using healthy control pools for normalization. Statistical analysis was performed and only 
miRNAs showing significant changes higher than two folds were considered. For these miRNAs, 
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bioinformatics target prediction and functional classification was performed using several oline 
databases. Briefly, for each miRNA a list of potential targets was downloaded from Targetscan 5.1. 
Next, target genes of each miRNA were analyzed using DAVID database and clustered in functional 
categories. Statistical analysis was performed for each cathegory to study  
relative enrichment compared to human genome background. miRNAs showing targets with 
biological significance in our study context were taken into account (See material and methods 
section and Figure 7 for detailed description of selection process).  
An integrated study of expression data, statistical analysis and bioinformatics functional studies led 
to a selection of a panel of 12 miRNAs with potential use as AKI biomarkers. The panel of miRNAs and 
a representative selection of their potential biological and functional relevance in our study context, 
as criteria for selection, are summarized in Tables 4 and 5. 
 
Table 4:  miRNAs to be tested as AKI biomarkers selected from the massive screening 
experiment.  P-values were calculated comparing miRNA expression in samples obtained at day 
of diagnosis (Day 0) of AKI patients with healthy control pools. 
 
 
 
 
 
 
 
 
 
 
 
 Fold Change p-value 
AKI Biomarkers   
hsa-miR-101-1 -2.75 0.061 
hsa-miR-127-3p -1.98 0.08 
hsa-miR-210 Undetermined - 
hsa-miR-126 -5.75 0.036 
hsa-miR-26b -7.52 0.024 
hsa-miR-29a -6.62  0.031 
hsa-miR-454 -5.81 0.015 
hsa-miR-146a  -8.50 0.021 
Ischemic AKI   
hsa-miR-27a -5.09 0.001 
Ischemic AKI Recovery   
hsa-miR-93* -22.03 0.017 
hsa-miR-487a -6.06 0.003 
Toxic and Septic AKI   
hsa-miR-10a 32.21 0.001 
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This final panel included different groups of microRNAs which were selected as potential biomarkers 
of several aspects of AKI. hsa-miR-126, hsa-miR-26b, hsa-miR-29a, hsa-miR-454 and hsa-miR-146a 
were selected as AKI biomarkers independently of its etiology. These miRNAs showed significant 
downregulation in AKI day 0 samples compared to control pools. hsa-miR-27a was selected as 
Ischemic AKI biomarker since this miRNA was downregulated in ischemic AKI patients but did not 
change its expression in samples from other etiologies. hsa-miR-93* and hsa-miR-487a drastically 
decreased their expression in ischemic AKI, but they reached healthy-like levels in recovered 
samples. Thus, these miRNAs were selected as ischemic AKI recovery markers. Finally hsa-miR-10a 
was selected as septic-toxic AKI biomarker. This miRNA was overexpressed in day 0 samples of 
patients with AKI of these etiologies. Moreover, bibliography data indicated that hsa-miR-10a is 
highly and specifically expressed in renal tissue (Landgraf P. et al., 2007).  
As can be observed in Table 4 hsa-miR-127-3p, hsa-miR-101-1 and hsa-miR-210 were included in the 
panel of miRNAs as AKI biomarkers, although they did not show significant changes or they were not 
detected in the massive screening experiment. miR-127-3p was included based on our data 
previously obtained in our in vitro and in vivo experimental models. miR-101-1 was also included 
because this miRNA was modulated in the initial microarray experiment performed in our in vitro 
model of H/R in NRK-52E cells and previous work of our group indicate that this miRNA is regulated 
by nutrient depletion in our system (data not shown). On the other hand, hsa-miR-210 was also 
included because increasing evidence demostrates that this miRNA is universally regulated by 
hypoxia (Rocha S., 2007) and, as indicated in previous sections of this work, hypoxia is a key 
component of AKI pathophysiology. 
After this initial selection experiment, this panel of miRNAs were validated in larger cohorts of 
patients, including a cohort of ICU patients with AKI and healthy controls and a cohort of patients 
who underwent cardiac surgery with CPB. 
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 Table 5: Functional classification of the putative targets of the miRNAs selected as potential AKI 
biomarkers. Functional categories showed in this table, clustering miRNAs targets, are extracted 
from KEGG and GO databases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
microRNA Functional Category p-value 
hsa-miR-101-1 Kidney development 8 x 10-5 
 Cell adhesion 1 x 10-3 
 Endocytosis 1.6 x 10-3 
hsa-miR-127-3p Ionic channel  1.4 x 10-4 
 Cell adhesion molecules 7.8 x 10-2 
 Epithelium development 7.9  10-2 
hsa-miR-210 Basement membrane  1.2 x 10-2 
 Actin cytoskeleton organization 4.1 x 10-2 
 Tube development 6.4 x 10-2 
hsa-miR-126 Kidney development 2 x 10-2 
 Microtubule-based transport 1.3 x 10-2 
 Cell-cell adherent junction 3.5 x 10-3 
hsa-miR-26b Epithelial tube morphogenesis 7.5 x 10-3 
 ATP binding 8.8 x 10-5 
 Cytoskeleton 7.6 x 10-3 
hsa-miR-29a Extracellular matrix 8.4 x 10-16 
 Focal adhesion  6.9 x 10-11 
 Collagen type IV 6.5 x 10-7 
hsa-miR-454 Tube development 1.3 x 10-7 
 Endocytosis 2.1 x 10-6 
 Vesicle mediated transport 3.5 x 10-5 
hsa-miR-146a Microtubule cytoskeleton  1.5 x 10-8 
 Intracellular transport 5.6 x 10-8 
 Kidney development 2.7 x 10-5 
hsa-miR-27a Kidney development 3.2 x 10-4 
 Endocytic activity 1 x 10-3 
 Epithelial tube morphogenesis 1.9 x 10-3 
hsa-miR-93* Endocytosis 3.7 x 10-7 
 GTPase regulator activity 1.1 x 10-6 
 Tube development 2.2 x 10-2 
hsa-miR-487a Tight junction 2.8 x 10-3 
 
Intracellular trafficking and 
secretion 
2.9 x 10-3 
 Adherent junction 4.7 x 10-2 
hsa-miR-10a Endocytosis 2.2 x 10-8 
 Adherent junction 3.7 x 10-8 
 Focal adhesion 1.1 x 10-6 
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7. - Serum miRNAs are accurate Biomarkers of AKI in ICU patients:  
In a first validation step, we studied the expression of the panel of miRNAs in a cohort of ICU patients 
with AKI compared to healthy controls. For this study, 35 ICU patients (19 of them presenting ATN 
and 16 with pre-renal AKI) and 20 healthy controls were selected from two collections stored in 
Hospital Ramón y Cajal-IRYCIS Biobank. Relevant clinical settings for these samples are presented in 
Table 6. 
Table 6: Clinical settings of ICU patient cohort and healthy controls.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miRNAs were quantified by qRT-PCR with LNA probes and expression data are presented as ΔCp. For 
normalization, only Spike-In RNA values were considered because this synthetic oligo, added during 
RNA extraction, was the most stable and reliable housekeeping, presenting no significant changes 
between healthy controls and AKI patients. We chose this method for data presentation to show all 
the control expression values individually, avoiding their normalization to an artificial value. It is 
important to notice that a unit difference in ΔCt values represents two fold change in the amount of 
 Healthy Control 
(n=20) 
AKI Patients 
(n=35) 
Age (years) 38.35 ± 11.42 64.9 ± 15.5 
Male (n, %) 12, 60% 28, 80% 
Female (n, %) 8, 40% 7, 20% 
AKI Etiology   
Ischemic N/A 9 
Toxic N/A 7 
Septic N/A 19 
AKIN Grade (Patient number) 
1 N/A 11 
2 N/A 9 
3 N/A 15 
Serum Creatinine (mg/dl)  
Day 0 (Diagnose) 0.76 ± 0.16 2.73 ± 4.47 
Day 7 (Recovery) N/A 1.35 ± 0.98 
AKI Origin   
Pre-renal  N/A 16 
ATN N/A 19 
Prognostic Score   
SOFA N/A 6.37 ± 3.68 
N/A: Not Applicable   
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input miRNA. Absolute differences between both samples can be calculated as 2ΔCp. Higher values of 
ΔCp indicate lower input amount of the studied miRNA.  
 
7.1. - Serum miRNAs as Diagnostic Biomarkers: 
Nearly all the selected miRNAs were successfully detected in serum samples. Only hsa-miR-454 and 
hsa-miR-487a could not be amplified, resulting in false positives derived from the screening method. 
Figure 21A shows expression values of selected miRNAs in Day 0 samples (Diagnosis).  
 
Figure 21: Serum microRNAs are diagnostic biomarkers of AKI in a cohort of ICU patients. (A) miRNAs were 
detected by qRT-PCR in serum samples from ICU patients at the moment of AKI diagnosis and compared to a 
cohort of healthy controls. miRNA serum levels are expressed as ΔCp values and data are presented as median 
and interquartile  range. Asterisk indicate statistical significance (*P<0.05 and ** P<0.01) (B) Spike-In raw Cp 
values demonstrating no significant changes between AKI patients and healthy controls.  
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In agreement with data obtained in the screening experiment, all the selected miRNA were markedly 
downregulated (higher ΔCp values) in AKI samples compared to healthy controls. Panel B shows raw 
Cp values of Spike-In RNA in these samples, showing no statistical significance between healthy and 
AKI samples (p-value= 0.081).  
ROC curve analysis was performed to study the sensitivity and specificity of these miRNAs as 
diagnostic tools for AKI. As can be observed in Figure 22 and Table 7, all miRNAs presented area 
under the curve (AUC) values between 0.9 and 1.  
 
 
 
 
Figure 22: Serum miRNAs show high 
diagnostic performance in ICU patients. 
ROC curve analysis of serum levels of the 
miRNAs included in our set discriminating 
AKI patients from healthy controls.  
 
 
Table 7: ROC Curve analysis of ICU patients in the moment of AKI diagnosis 
compared to healthy control.  
 
 
 
 
 
 
 
 
 
These data demonstrate that serum miRNAs are a powerful diagnostic tool for AKI with almost 100% 
of sensitivity and specificity.  
microRNA 
ROC Analysis Day 0 (Diagnosis) 
AUC S.E.M. p-value 
miR-101-1 1.000 0.000 0.000 
miR-210 0.935 0.034 0.000 
miR-126 0.979 0.015 0.000 
miR-26b 1.000 0.000 0.000 
miR-29a 0.948 0.27 0.000 
miR-146a 1.000 0.000 0.000 
miR-27a 0.955 0.025 0.000 
miR-93* 0.942 0.029 0.000 
miR-10a 1.000 0.000 0.000 
miR-127-3p 0.939 0.033 0.000 
  
111 
 
  
6 RESULTS 
7.2. - Serum miRNAs levels correlate with AKI severity:  
At the moment, AKI severity is determined based on changes in serum creatinine or urine output 
produced during a determined time-period. This method delays patient classification with potential 
dramatic consequences in patient management. Based on this situation, we wanted to assess if 
serum miRNAs could determine AKI severity earlier than the current diagnostic tools.  
As can be observed in Figure 23, Spearman correlation analysis demonstrated that ΔCp values of 
miR-210, miR-126, miR-29a and miR-146a significantly correlate with patient classification based on 
AKIN criteria (miR-210 p-value=0.001; miR-126 p-value=0.021; miR-29a p-value=0.009; miR146a p-
value=0.008). 
These results demonstrate that serum miRNA levels could indicate AKI severity in a single 
determination avoiding patient classification delaying produced by systems based on creatinine 
relative changes.  
 
Figure 23: Serum levels of miR-210, miR-126, miR-29a and miR-146a correlates with AKI 
severity. Serum miRNAs were detected by qRT-PCR in samples from ICU patients at the 
moment of AKI diagnosis. miRNA expression levels are presented as ΔCp values and each 
patient is represented by an individual dot. Spearman correlation was performed for each 
miRNA and p-values are shown in the corresponding plots. 
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7.3. - Serum miRNAs distinguish between Intrinsic and Pre-renal AKI:  
As indicated in previous section of this work, AKI could present an intrinsic origin, when kidney 
damage is located in renal parenchyma, or pre-renal origin when the kidney cannot function properly 
due to poor perfusion (Liaño F et al., 2011; Nejat M. et al., 2012). Discrimination between both AKI 
origins to apply early and appropriate treatment would be a valuable characteristic for an AKI 
biomarker.  
Based on this clinical need, we wanted to assess whether our panel of miRNAs could differentiate 
between intrinsic and pre-renal AKI. For this purpose, we studied the expression of serum miRNAs in 
our cohort of ICU patients, comparing ΔCp values between those patients with pre-renal AKI and 
those with intrinsic AKI. Pre-renal AKI was diagnosed when AKI was recovered in less than 72 hours.  
As can be observed in Figure 24, miR-210, miR-126, miR-29a and miR-146a present significant higher 
ΔCp values in those patients with pre-renal AKI compared to intrinsic AKI indicating the serum levels 
of these miRNAs could be used to differentiate and diagnose AKI origin.  
 
Figure 24: Serum levels of miR-210, miR-126, miR-29a and miR-146a differentiate Pre-renal 
from Intrinsic AKI. Serum miRNAs were detected by qRT-PCR in samples from ICU patients at 
the moment of AKI diagnosis. miRNA expression levels are presented as ΔCp values and data 
are expressed as median and interquartile range. Asterisks indicate statistical significance 
(*P<0.05 and ** P<0.01). 
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7.4. - Serum miRNAs as potential biomarkers of long-term outcome:  
We studied the expression of our panel of miRNAs in serum samples obtained 7 days after AKI 
diagnosis, time-point when serum creatinine values are almost recovered (Table 6), indicating that 
renal function is restored and AKI is clinically resolved.  
As can be observed in Figure 25A, the selected miRNAs still shown downregulated values in AKI 
patients compared to healthy controls. These data agree with the results obtained in the screening 
experiment, and they could indicate that, although creatinine values are restored, it is possible that 
there is still a tissue and cellular damage that could be pointed out by miRNAs. Raw Cp data of Spike-
In RNA (Figure 25B) show no significant changes between patients and healthy controls.   
 
Figure 25: Serum miRNAs levels remain altered when AKI is clinically resolved. (A) miRNAs were detected by 
qRT-PCR in serum samples from ICU patients obtained at 7 days of evolution and compared to a cohort of 
healthy controls. miRNA serum levels are expressed as ΔCp values and data are presented as median and 
interquartile range. Asterisks indicate statistical significance (*P<0.05 and ** P<0.01) (B) Spike-In raw Cp values 
demonstrating no significant changes between AKI patients and healthy controls.  
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All miRNAs present AUC values between 0.8 and 1 in ROC analysis (Figure 26, Table 8). Remarkably, 
miR-146a still presents a 100% specificity and sensitivity.  
 
 
 
 
Figure 26: Serum miRNAs levels show high 
discriminative value between healthy controls 
and AKI patients at 7 days of evolution. ROC 
curve analysis of serum levels of the miRNAs 
discriminating AKI patients at 7 days of evolution 
after diagnosis from healthy controls.  
 
  
Table 8: ROC Curve analysis of ICU patients at 7 days of evolution compared to healthy 
controls.  
 
 
 
 
 
 
 
 
Taken together all these data demonstrate that the panel of selected miRNAs are accurate 
biomarkers of AKI in ICU patients, showing high sensitivity and specificity for diagnosis. Moreover, 
these biomarkers can differentiate between intrinsic and pre-renal AKI, and they show a significant 
correlation with renal damage degree. miRNA expression values at day 7 remains altered instead of 
normalization, which could reflect the persistence of cellular and tissue damage. This feature 
suggests that these molecules could constitute a mark of renal injury when renal function is 
aparently restored by classical parameters.  
microRNA 
ROC Analysis Day 7 (Recovery) 
AUC S.E.M. p-value 
miR-101-1 0.961 0.039 0.000 
miR-210 0.861 0.064 0.000 
miR-126 0.903 0.049 0.000 
miR-26b 0.995 0.007 0.000 
miR-29a 0.867 0.063 0.000 
miR-146a 1.000 0.000 0.000 
miR-27a 0.845 0.064 0.000 
miR-93* 0.776 0.084 0.003 
miR-10a 0.987 0.015 0.000 
miR-127-3p 0.874 0.054 0.000 
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8. - Serum miRNAs as biomarkers of AKI after cardiac surgery: 
Sublethal AKI is one of the most frequent complications after cardiac surgery (36% Incidence) and its 
severity is determinant for patient outcome (Liaño F et al., 2011). Due to this clinical relevance, we 
hypothesized if our panel of miRNAs could predict AKI development in patients undergoing cardiac 
surgery with cardiopulmonary bypass.  
For these experiments, serum samples were collected from a cohort of patients including adults with 
low and high risk of AKI development as well as pediatric patients. Clinical settings for these patients 
are summarized in Table 9.  
 
 Table 9: Clinical settings of cardiac surgery patient cohort.  
 
 
 Group IA 
(n=10) 
Group IB 
(n=10) 
Group II 
(n=15) 
Group III 
(n=4) 
Age (years) 65.6 ± 10.4 
52.3 (10.6-
108.4)* 
74.8 ± 6.9 62.0 ± 12.3 
Gender (Men/Women) 5/5 7/3 4/10 5/2 
BMI (kg/m2) 27.5 ±3.6 14.5 ± 2.3 26.7 ± 3.7 28.1 ± 2.7 
CPB Time (min) 96.6 ± 31.7 58.1 ± 20.3 101.7 ± 34.7 105.2 ± 33.6 
ICU L.O.S. (days) 3 (2 – 6)* 5 (3-5)* 6.5 (2 – 10)* 7 (2 – 12.5)* 
Basal Serum Cr. (mg/dl) 0.9 ± 0.1 0.57 ± 0.1 1.2 ± 0.3 0.95 ± 0.3 
24h Serum Cr. (mg/dl) 0.8 ± 0.2 0.55 ± 0.1 1.1 ± 0.4 1.02 ± 0.6 
Discharge Serum Cr 
(mg/dl) 
0.8 ± 0.2 0.5 ± 0.1 1.19 ± 0.4 1.19 ± 0.6 
Risk Scores    
LogEuroSCORE 4.08 ± 3.05 N/A 9.7 ± 4.4 9.8 ± 7.8 
Cleveland Score 1.8 ± 0.9 N/A 3.83 ± 1.0 4.25 ± 1.0 
SRI Score 1 ± 0.5 N/A 3.45 ± 0.5 3.0 ± 0.5 
AKI Development     
RIFLE Cr  (n) 1 1 4 3 
AKIN Cr.  (n) 4 1 9 3 
Cr. Kinetics  (n) 1 1 7 2 
BMI: Body Mass Index 
N/A:  Not Applicable 
LOS: Length of Stay. 
Cr: Creatinine. 
* Data expressed as median, 25th – 75th percentiles 
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As currently available AKI definitions can lead to quite different patient classification, we determined 
AKI development using the serum creatinine criteria of the RIFLE, AKIN and creatinine kinetics 
classifications. miRNA were detected by qRT-PCR using LNA probes and, as indicated in previous 
sections, miRNA expression levels are expressed as ΔCt values using Spike-In RNA as housekeeping 
control. 
 
8.1. – Serum miRNAs as early Biomarkers of AKI in cardiac surgery patients:  
As indicated in material and methods section, in this cohort several serum samples at predefined 
time points before and after surgery were obtained for each patient. In contrast with ICU cohort, 
where patients are included in the study when AKI is already established, this experimental design 
allows a precise AKI development monitoring, including the features which take place in the days 
previous to diagnosis. 
Based on this possibility, we analyzed the expression of our panel of miRNAs during the days before 
AKI diagnosis. miRNAs were detected by qRT-PCR and expression levels are indicated as ΔCp values. 
Spearman Rho correlation coefficient was calculated to find out statistically significant correlations 
between miRNA expression and time-points before AKI diagnosis.  
As previously indicated, AKI was determined by RIFLE, AKIN and Creatinine kinetics criteria. The 
number of patients who developed AKI in each classification was 9, 17 and 11 respectively. We 
analyzed the expression levels of the miRNAs in the three days prior to AKI episode. Although a 
tendency could be observed in all classifications, only AKIN criteria reached statistical significance, 
probably due to the higher number of cases included.  
As can be observed in Figure 27, miR-26b, miR-146a, miR-93* and miR-127-3p show a progressive 
downregulation of their expression levels during the previous days to AKI diagnosis based on serum 
creatinine criteria. Remarkably, miR-146a shows a pronounced and significant downregulation during 
the days prior to AKI. These studies demonstrate that this miRNA is a powerful diagnostic biomarker, 
correlating with previous results obtained in ICU patients, where miR-146a showed 100% specificity 
and sensitivity. 
Taken together these data demonstrate that serum miRNAs are diagnostic biomarkers of AKI, in 
agreement with the data previously obtained in ICU patients. Moreover, miRNAs can detect and 
monitor AKI development several days before serum creatinine, becoming early AKI biomarkers 
which can contribute to improve patient management and outcome after surgery. 
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Figure 27: Serum miRNAs downregulation occurs days before serum creatinine increases. miR-26b, 
miR-146a, miR-93* and miR-127-3p serum levels are expressed as ΔCp values and data is presented as 
individual dots. AKI was diagnosed based on AKIN serum Cr criteria. Spearman Rho correlation 
coefficient was calculated and p-values are indicated in each panel.  
 
8.2. - Serum miRNAs are Biomarkers of AKI Predisposition: 
In the next step, we wanted to determine whether serum miRNA exhibit differential expression 
between patients which develop AKI after surgery compared to those who do not develop AKI. For 
this purpose, all the miRNAs included in our panel were determined in basal serum samples, 
obtained before surgery. Although some of them presented significant changes depending on the 
classification used (data not shown), only those miRNAs showing significant changes in all 
classifications were considered as real biomarkers of AKI development after cardiac surgery.  
Spike-In raw Cp values do not significantly change between patients which develop AKI and those 
which do not develop AKI after surgery in any of the used classifications (RIFLE: p-value=0.450; AKIN: 
p-value=0.725; Cr Kinetics: p-value=1) (Figure 28A).  
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Figure 28: Serum miRNAs estimated before surgery are predictive biomarkers of AKI development. (A) 
Spike-In raw Cp values are shown indicating no statistical differences between patients who develop AKI 
compared to those who did not develop AKI after surgery. (B) Serum levels of miR-26b, miR-27a, miR-93* and 
miR-127-3p were detected by qRT-PCR in serum samples obtained before surgery. miRNA serum levels are 
expressed as ΔCp values and data are presented as median and interquartile range. Asterisks indicate statistical 
significance (*P<0.05 and ** P<0.01). 
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As can be observed in figure 28B, miR-26b, miR-27a, miR-93* and miR-127-3p are significantly 
downregulated (higher ΔCp values) in those patients who develop AKI after surgery, compared to 
those who do not develop AKI. Interestingly, those miRNAs which were selected as biomarkers of 
ischemic AKI (Table 4) are significantly regulated in this system, in agreement with the data obtained 
in the initial screening experiment.  
ROC analysis was performed to study the diagnostic potential of these miRNAs as predictors of AKI. 
As it is shown in Figure 29 and Table 10, all the studied miRNAs present significant AUC values 
between 0.7-0.9, depending on the AKI definition criteria used, demonstrating high diagnostic value.  
 
Figure 29: Serum miRNAs levels indicate AKI predisposition. ROC curve analysis of serum levels of miR-26b, 
miR-27a, miR-93* and miR-127-3p discriminating between patients who develop AKI and those who do not 
develop AKI after surgery. 
 
Table 10: ROC Curve analysis of serum miRNAs estimated in samples obtained before surgery.  
 RIFLE AKIN Creatinine Kinetics 
 AUC p-value AUC p-value AUC p-value 
miR-26b 0.821 0.006 0.722 0.024 0.908 0.000 
miR-27a 0.844 0.007 0.725 0.022 0.888 0.000 
miR-93* 0.815 0.007 0.719 0.026 0.887 0.000 
miR-127-3p 0.783 0.016 0.795 0.003 0.863 0.001 
 
Similar studies were performed with serum samples obtained immediately after surgery. Although all 
the miRNAs are also downregulated in patients which develop AKI, only miR-27a and miR-93* show 
significant changes depending of the AKI definition criteria used (Figure 30).  
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Figure 30: Serum levels of miRNAs estimated immediately after surgery do not discriminate later AKI 
development. Serum levels of miR-26b, miR-27a, miR-93* and miR-127-3p were detected by qRT-PCR in 
serum samples obtained immediately after surgery. miRNA serum levels are expressed as ΔCp values and 
data are presented as median and interquartile  range. Asterisks indicate statistical significance (*P<0.05).  
 
ROC analysis of these data indicates lower diagnostic potential with AUC values between 0.6-0.7 
(Figure 31, Table 11).  
Taken together, these data demonstrate that basal levels of miR-26b, miR-27a, miR-93* and miR-
127-3p are promising biomarkers of AKI predisposition, although not significant differences were 
found after surgery. 
  
121 
 
  
6 RESULTS 
 
Figure 31: Serum levels of miR-26b, miR-27a, miR-93* and miR-127-3p immediately after surgery do not 
exhibit high sensitivity and specificity for AKI. Discriminative analysis was performed comparing those patients 
who develop AKI and those who do not develop AKI after surgery.  
 
Table 11: ROC Curve analysis of serum miRNAs estimated in samples obtained immediately after 
surgery.  
 
 
 RIFLE AKIN Creatinine Kinetics 
 AUC p-value AUC p-value AUC p-value 
miR-26b 0.629 0.250 0.601 0.293 0.66 0.114 
miR-27a  0.694 0.083 0.676 0.067 0.727 0.031 
miR-93* 0.698 0.077 0.697 0.041 0.731 0.028 
miR-127-3p 0.623 0.272 0.672 0.075 0.664 0.118 
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In this work, we have identified and characterized several miRNAs as key molecules involved 
in kidney response to I/R as well as their role as promising AKI biomarkers. Identification of molecular 
mechanisms underlying kidney ischemic injury and recovery is essential for improving our 
understanding of AKI pathophysiology and new therapeutic target identification. Moreover, 
discovery of earlier and more accurate biomarkers could significantly improve AKI patient 
management in several clinical contexts, such as ICU, renal transplant or cardiac surgery.  
We have identified rno-miR-127 and its human homologous hsa-miR-127-3p as important 
mediators of the proximal tubule response to I/R. rno-miR-127 induction during I/R is a cytoskeleton 
protection mechanism which prevents actin depolimerization and promotes cell adhesion by 
preventing FAC disassembly and TJ disorganization. Moreover, we have identified KIF3B, a 
component of kinesin II complex (Manning BD and Snyder M, 2000), as a real target of rno-miR-127 
in proximal tubule cells, with potential implications in cell trafficking. In addition, we have 
demonstrated that hsa-miR-127-3p and a panel of serum miRNAs identified in this work (miR-101-1, 
miR-210, miR-126, miR-26b, miR-29a, miR-146a, miR-27a, miR-93* and miR-10a) are precise 
biomarkers of AKI in ICU and cardiac surgery patients. Indeed, miR-210, miR-126, miR-29a and miR-
146a can discriminate between pre-renal and intrinsic AKI and their expression levels correlate with 
AKI severity. Moreover, miR-26b, miR-27a, miR-93* and miR-127-3p are biomarkers of AKI 
predisposition and miR-26b, miR-146a, miR-93* and miR-127-3p indicate kidney damage and AKI 
development before serum creatinine increases.  
Several studies have identified miRNAs modulated during renal I/R injury (Wei Q et al., 2010; 
Shapiro MD et al., 2011) but none have pointed miR-127 as a regulated miRNA in this context. Within 
our knowledge, this is the first study identifying and characterizing miR-127 in kidney response to I/R. 
Previous publications have described miR-127 as an ubiquitously expressed microRNA which can be 
detected in several human and rat tissues including kidney and proximal tubule cells (Landgraf P et 
al., 2007; Linsen SE et al., 2010). Aditionally, this microRNA is also expressed in other human 
epithelial cells such as breast (Bockmeyer CL et al., 2011) and lung (Bhaskaran M et al., 2009) 
Our results demonstrated for the first time that miR-127 is regulated by ischemia in vitro and 
in vivo. Several microRNAs modulated by hypoxia have been identified (Crosby ME et al., 2009) but 
miR-127 was not included among them. It is important to notice that our models (in vitro and in vivo) 
not only include low oxygen levels, but also serum and nutrient deprivation, which can explain 
miRNAs different profile between hypoxia and ischemia conditions. In this regard, it has been 
described that miR-127 is involved in the response of pancreatic cells to glucose availability to 
produce insulin secretion (Bolmeson C et al., 2011). In any case, our results indicate a great 
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correlation between the expression of rno-miR-127 in both the in vitro and in vivo model in rat. rno-
miR-127 is increased during hypoxia and Ischemia and at 1h and 24 hours of reperfusion respectively, 
time points when cellular or renal tissue damage is maximum in this model (Sáenz-Morales D et al., 
2006; Conde E et al., 2012). These results indicate that miR-127 could be a potential renal tissue 
damage biomarker, as we have probed in AKI patients, and it could have a potential role in proximal 
tubule response to I/R as it will be further discussed.  
On the other hand, we observed different miR-127 expression pattern in human cells (HK-2), 
where its expression is increased mainly during complete medium hypoxia and along reperfusion. 
Although miR-127 is located in a cluster of microRNAs whose structure is conserved among 
mammals, miR-127 promoter region shows very low sequence conservation between rat and human. 
Due to this fact, transcription factor binding sites exclusive for each species could contribute to the 
observed different regulation (Song G and Wang L, 2009). Moreover, in human cells, hsa-miR-127-3p 
is located in a CpG island which could be submitted to a fine tissue specific regulation by 
methylation. In several human tissues and in some types of cancer, DNA hypermethylation leads to 
repression of miR-127 expression (Lujambio A et al., 2010). Surprisingly, evidence in rat 
hepatocarcinogenesis models reveals that hypomethylation of DNA, induced by a methyl-deficient 
diet, decreases miR-127 expression (Tryndyak VP et al., 2009), indicating that although epigenetic 
DNA regulation can explain differences in miRNAs expression between species, miR-127 regulation 
by methylation is still controversial. 
Our interference experiments in vitro demonstrated for the first time that HIF-1α is one of 
the regulators of miR-127 expression, among other mechanisms. Moreover, HIF-1α is induced during 
H/R and I/R as we have previously demonstrated (Conde E et al., 2012). A putative HRE element 
downstream miR-127 sequence, highly conserved among species, was bioinformaticaly predicted. 
However, CHIP analysis did not confirm HRE functionality. This could indicate that other HRE 
elements not predicted by the bioinformatic analysis could be responsible for miR-127 regulation in 
our in vitro system. Besides, this regulation by HIF-1α could be indirect. In this regard, a potential 
crosstalk between c-myc and HIF-1α could be suggested in this case, since c-myc is a known regulator 
of miR-127 expression in leukemia cells (Leucci E et al., 2010). Additionally, HIF can modulate the 
expression of histone demethylases involved in chromatin remodeling (Beyer S et al., 2008), which is 
needed for the expression of some essential genes for the hypoxic response such as EPO (Rocha S, 
2007) or miRNAs (Kim GH et al., 2011). 
We have identified here for the first time KIF3B as a real target of rno-miR-127 in rat 
proximal tubule cells during H/R. Proximal tubule cells present a developed endocytosis apparatus 
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involved in urine protein absorption and membrane receptors exposition and recycling (Brown D et 
al., 2009). KIF3B has been involved in late endosomes and lysosomes localization (Brown CL et al., 
2005). However, recent work has demonstrated that KIF3B is also responsible for receptor and ionic 
transporter localization in polarized epithelial cell membrane. In this regard, it has been evidenced 
that KIF3B knockdown impairs cell polarization in intestine epithelial cells (Gao N and Kaestner KH, 
2010) and it is important for the correct localization of kidney anion exchanger 1 and Chloride/proton 
antiporter CLC-5 in proximal tubule cells (Duangtum N et al., 2011; Reed AA et al., 2010). In addition, 
KIF3B has been unveiled as a specific regulator of albumin and transferring uptake in polarized kidney 
cells. KIF3B overexpression promotes internalization of membrane vesicles containing cubilin and 
megalin receptors, decreasing proximal tubule protein reabsorption capacity (Reed AA et al., 2010). 
In this work, rno-miR-127 blockade leads to KIF3B overexpression and endocytic activity increase. 
Thus, miR-127 up-regulation observed during I/R could result in KIF3B downregulation and proximal 
tubule cell trafficking impairment, as observed during renal I/R injury (Bonventre JV and Yang L, 
2011). Moreover, miR-127 induction and trafficking impair trough KI3FB inhibition could lead to 
tubular cell protection since cell trafficking requires high levels of ATP, compromised during renal I/R. 
Regarding a potential protective role of miR-127 in response to I/R, this work describes for 
the first time the effects of rno-miR-127 modulation in actin cytoskeleton organization and adhesive 
structures integrity during I/R injury. miR-127 overexpression prevents FAC disassembly and TJ 
disruption and epithelial barrier impairment, all of them essential for kidney function. The molecular 
mechanisms responsible for these effects need to be further investigated, but the regulation of 
intestinal TJ permeability by miRNAs has been recently described (Ye D et al., 2011). Other 
components of cell-cell adhesion structures such as E-cadherin are also regulated in kidney by 
miRNAs, in particular, miR-200 family (Xiong M et al., 2012). Furthermore, E-cadherin function and AJ 
integrity could be indirectly regulated by miR-127 target KIF3B. This factor directly interacts with 
plakophilin-4, which is involved in E-cadherin maintenance in the cell surface and its connection to 
cytosleketon. Moreover, KIF3B is a regulator of Rho-A activity during stress fibers formation 
(Apodaca G, 2001), that has been previously observed in proximal tubule cell response to I/R (Sáenz-
Morales D et al., 2006). Therefore, rno-miR-127 induction during I/R and H/R could protect cell-
matrix and cell-cell adhesions trough KIF3B downregulation, among other mechanisms not yet 
identified, contributing to cell structure maintenance and epithelial barrier function.  
Since miRNAs can regulate injury and repair cellular processes, functional studies of the 
miRNAs included in our panel of AKI biomarkers may provide additional worthy information for AKI 
biology understanding. This is the case of miR-127-3p, which has been unveiled in our work as an 
accurate biomarker of ischemic AKI in cardiac surgery patients and also as a regulator of proximal 
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tubule cell adhesion and trafficking. In addition, due to their critical role in pathophysiological 
processes, miRNAs could be considered as new potential therapeutic targets.  
 hsa-miR-127-3p secretion to supernatants of proximal tubule cell cultures pointed out the 
potential role of extracellular miRNAs as AKI biomarkers. Our data show a great correlation between 
extracellular and intracellular expression pattern of miR-127-3p in HK-2 cells submitted to H/R. 
miRNA secretion mechanisms and regulation are not completely understood yet. Recent evidence 
indicates that miRNA secretion to extracellular fluids is a selective process and that secreted miRNAs 
do not reflect the miRNA profile of the parental cells (Mittelbrunn M et al., 2011). However, it has 
been also demonstrated that some miRNAs, such as let-7 family, exhibit correlating intra- and 
extracellular levels (Koh W et al., 2010).  
miRNAs quantification in serum samples is not standardized yet and several technical 
questions need to be further optimized. Both serum and plasma have been used for miRNA 
biomarker discovery leading to extremely different results. Plasma contains a higher concentration of 
circulating miRNAs. However, these plasma miRNAs principally derive from platelets (McDonald JS. et 
al., 2011). Based on this evidence, we finally chose serum to perform our studies, since platelet 
contamination could introduce a great error in miRNA profiling and quantification.  
Several protocol variations have been used for serum miRNA retrotranscription after total 
RNA extraction. Some approaches normalize RNA amount among reactions, while other studies, such 
as this work, use a constant volume of eluted RNA for this purpose. Due to the extremely low 
amount of miRNAs contained in 200 µl of serum, RNA quantification by Nanodrop or Bioanalyzer 
chips is not reliable enough. Moreover, we have not found correlation between RNA concentration, 
estimated by both methods, and miRNA amplification (data not shown). In addition, constant RNA 
amount strategy leads to a disproportionate representation of the original volumes of these miRNAs 
were derived from (Gallo A. et al., 2012). A constant elution volume during RNA extraction and a 
constant RNA volume for retrotranscription, represent an invariant volume of serum, potentially 
allowing miRNA concentration calculation using standard curves and absolute quantification 
strategies.  
Data normalization is other of the key points for reliable serum miRNA quantification. Several 
housekeeping approaches have been proposed such as small nucleolar RNAs, constant miRNAs 
previously tested in tissue studies, or synthetic Spike-in RNAs (For review Reid G. et al., 2011). In our 
experience, few small nuclear RNAs could be detected in serum samples and those which could be 
quantified did not show stable levels across samples. Small ribosomic RNAs, such as 5s, could not be 
amplified in our system either. Moreover, some of the miRNAs which have been widely used as 
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housekeeping such as miR-16 or miR-let-7a were modulated in our samples. In addition, several 
studies point out that the principal source of technical variation in serum miRNA quantification is the 
RNA extraction step (Andreasen D.  et al., 2010; McDonalds JS. et al., 2011). Based on these 
evidences, we finally chose Spike-In normalization method by adding the RNA oligonucleotides 
during the first steps of RNA extraction.  
In this work, after setting up the protocols as well as quantification and normalization 
methods, we identified and validate, in a pilot study, a set of miRNAs, including miR-101-1, miR-127-
3p, miR-210, miR-126, miR-26b, miR-29a, miR-146a, miR-27a, miR-93* and miR-10a, as potential 
biomarkers of AKI in ICU and cardiac surgery patients. Genome wide profiling experiments have 
demonstrated that some of these miRNAs (miR-10a, miR-27a, miR-29a, miR-101 and miR-210) are 
highly expressed in human kidney tissue (Liu GC et al., 2004; Landgraf P et al., 2007). Indeed, several 
studies have confirmed the presence of some of these miRNAs in serum microvesicles and miR-101, 
miR-27, miR10a, miR-146a, miR26b and miR-29a have been specifically detected in microvesicles 
derived from renal carcinoma cells, with a potential role in tumor angiogenesis regulation (Hu G et 
al., 2012; Grange C et al., 2011).  
Some of these miRNAs have been related to kidney injury in several studies. miR-146a 
regulates it expression in kidney in mice submitted to renal I/R injury (Godwin et al., 2010). 
Moreover, increased levels of this miRNA are present in renal tissue and urine of patients with IgG 
nephropathy. This study also demonstrates that, in agreement with our data, miR-146a levels 
correlates with the clinical severity of injury, indicating that this miRNA could be a modulator of the 
pathophysiological mechanisms of kidney injury (Wang G. et al., 2011).  
On the other hand, miR-29a has been related to kidney fibrosis regulation and chronic kidney 
disease progression. This miRNA is regulated by TGF-β and it expression has been related to fibrosis 
prevention, by avoiding ECM deposition in renal parenchyma (Patel V and Noureddine L V, 2012).   
In a recent study of Lorenzen JM. et al., miR-210 expression levels in plasma predicts survival 
in critically ill patients with AKI. In contrast with our data, in this study AKI patients present higher 
levels of miR-210 compared to healthy controls, probably due to the use of plasma samples instead 
of serum. Survival was studied 4 weeks after starting of RRT. miR-210 levels were significantly higher 
in non-survivor patients compared to survivors (Lorenzen JM. et al., 2011).  
A recent work from Saikumar J. et al. has identified miR-21, miR-155 and miR-18a as miRNAs 
regulated in kidney tissue during AKI. Moreover, urinary levels of miR-21 and miR-155 are increased 
in AKI patients compared to healthy volunteers (Saikumar J. et al., 2012). Although these miRNAs 
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were not finally selected in our panel of miRNAs of interest, in agreement with this study, miR-155 
and miR-21 were also modulated in our initial screening experiment (data not shown). These data 
suggest that miRNAs associated with AKI could be modulated in several body fluids, particularly in 
serum and urine, presenting a potential expression correlation.  
In a first step of proof-of-concept studies, our data in ICU patients demonstrate that our 
panel of miRNAs presents a high diagnostic potential with AUC values between 0.9 and 1 in ROC 
analysis. This discriminative power is higher than that obtained with other AKI biomarkers currently 
in development. Plasma and urinary NGAL, which have demonstrated the highest diagnostic 
potential up to the moment, present AUC values between 0.78 and 0.86 in adult ICU studies. Cystatin 
C and IL-18 have demonstrated AUC values of 0.7 and 0.62 respectively (For review Sirota JC. et al., 
2011). Our results demosnstrate that serum miRNAs show a very high diagnostic value in adult 
population, compared with other biomarkers which only reach sensitivity and specificity values close 
to 100% in pediatric ICU populations.  
Other characteristic of a valuable AKI biomarker is the ability to achieve an objective and 
precise quantification or renal injury. Serum levels of miR-210, miR-126, miR-29a and miR-146a show 
a significant and robust correlation with AKIN stage classification. This feature indicates that these 
miRNAs could be biomarkers of AKI severity, since alterations in these miRNAs could be underlying 
AKI development. Quantification of these miRNAs could indicate AKI severity in a single 
determination, allowing earlier patient classification. Among the wide range of new AKI biomarkers, 
only serum Cystatine-C present this ability (Soto K. et al., 2010), although others such as plasma 
NGAL can predict AKI progression in severity (Koyner JL. et al., 2010).  
Another goal of the new generation of AKI biomarkers is the ability to differentiate between 
pre-renal and intrinsic AKI. Clinical decision making is currently non-optimal and too slow with the 
present diagnostic methodologies. At the moment, pre-renal AKI is treated by vigorous hydration and 
waiting for kidney functional damage reversal. Waiting for reversal delays diagnosis and appropriate 
intervention in those patients which require more than rehydration treatment. Thus new diagnostic 
tools are required instead of diagnosis by exclusion. Several biomarkers have demonstrated ability to 
detect pre-renal AKI. KIM-1, Cystatin-C and IL-18 increase their concentration in pre-renal patients 
compared to no-AKI patients. However, these findings are still controversial and several studies 
indicate that these biomarkers as well as NGAL do not change its concentration in pre-renal patients, 
showing similar levels to no-AKI patients (Nickolas TM. et al., 2008; Payen D and Legrand M, 2011; 
Nejat M. et al., 2012).  
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Our data demonstrate that serum levels of miR-210, miR-126, miR-146a and miR-29a are 
significantly downregulated in pre-renal patients compared to established AKI patients, indicating 
that these biomarkers can discern between both AKI origins. Recently, pre-renal AKI has been 
defined as a mild form of intrinsic AKI which can be reversed, rather than two differents forms of AKI 
(Nejat M et al., 2012). Interestingly, target genes of these miRNAs include critical genes involved in 
renal homeostasis and regeneration after injury such as E2F3, target gene of miR-210 involved in cell 
cycle regulation (Giannakakis A et al., 2008) and Collagen I and IV, miR-29a targets and essential 
components of renal ECM (Wang B et al., 2012). Additionally, secretion of miR-126 by endothelial 
cells is involved in reprogramming of hypoxic resident renal cells to a regenerative program 
(Cantaluppi V et al., 2012).  
On the other hand, both initial cluster analysis and ICU patient data when creatinine is 
normalized demonstrate that serum miRNA profile can distinguish between different recovery 
degrees and maintain altered levels even when renal function is reestablished. AKI is a complex 
syndrome which includes not only functional injury but also structural damage. In the last years, 
accumulating evidence demonstrates that, although the majority of patients present functional 
recovery after AKI, estimated by serum creatinine, there is a remaining tissue damage. This sub-
clinical injury leads to decreased renal reserve and ultimately long-term adverse outcomes such as 
Chronic Kidney Disease (Murugan R and Kellum JA, 2011). Serum miRNAs could constitute new 
biomarkers of kidney structural damage indicating underlying tissue injury even when renal function, 
estimated by classical parameters, is restored. Our data demonstrate that serum miRNAs levels 
remain downregulated at 7 days of evolution after AKI. In agreement with this feature, it has been 
recently demonstrated that CKD development is associated with a lower circulating miRNA 
concentration in serum (Neal CS. et al., 2011).  
Due to their key role in regulation of cell function, miRNAs can also constitute a biological 
mechanism involved in long-term pathology development after AKI. In this regard, maintained 
hypoxia has been described as an important factor in development of CKD and other renal 
pathologies (Heyman SN et al., 2008). Thus miRNAs regulated by hypoxia could have important 
functions in these events. miR-210, one of the miRNAs included in our panel, is one of the most 
characterized miRNA regulated by hypoxia, with essential cellular adaptative functions (For review 
Chan YC. et al., 2012). Thus, maintained deregulation of this miRNA, among others, could constitute a 
mechanism underlying long-term pathology development and serum levels could be used to 
monitoring and predict patient outcome.  
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Other important characteristic for an AKI biomarker is the ability to provide information 
about the etiology of the injury. IL-18 and NGAL present higher levels in septic AKI patients compared 
to non-septic AKI (Bagshaw SM. et al., 2007; Bagshaw SM. et al., 2010) and they also change their 
expression levels in contrast and cisplatin-induced AKI (Sirota JC. et al., 2011). However, despite 
these promising evidences, up to the moment none of them have demonstrated ability to discern AKI 
etiology in a cohort of mixed patients including ischemic, toxic and septic patients. Our screening 
data demonstrate that serum miRNA expression profile could distinguish between patients with 
several AKI etiologies, probably due to the different biological mechanism underlying each one of 
them. Thus, a careful selection of specific miRNAs for each etiology could undoubtedly indicate AKI 
etiology in a single determination, with potential application in complex cohorts of mixed patients. 
However, this hypothesis needs to be further investigated.  
Early AKI detection before functional changes are detectable is another valuable 
characteristic of novel biomarkers. To assess this issue, in a second validation step, we studied the 
expression of our panel of miRNAs in a cohort of patients which underwent cardiac surgery with CPB. 
This experimental design offers a context where the moment and the severity of kidney insult is 
known and patient outcome can be closely followed. Several biomarkers have been tested in this 
clinical context to predict AKI development immediately or few hours after intervention. They have 
demonstrated very high predictive values in pediatric populations but more variable results in adults. 
NGAL presented AUC values ranging from 0.54 to 0.87, IL-18 from 0.55 to 0.87, Cystatin-C from 0.73 
to 0.76 and from 0.68 to 0.78 in the case of KIM-1 (For review Mariscalco G. et al., 2011; Siew ED. et 
al., 2011).  
Our results demonstrated that basal levels of miR-26b, miR-27a, miR-93* and miR-127-3p, 
measured before surgery, can robustly predict AKI development after CPB, independently of the AKI 
criteria used for diagnosis. They show a very high predictive potential with AUC values comprised 
between 0.7 and 0.9. This evidence demonstrates that several miRNAs included in our panel are 
robust markers of AKI predisposition. Only KIM-1 has demonstrated this ability by predicting stage 3 
AKI after CPB with an AUC value of 0.8 (Koyner JL. et al., 2010). However, miRNAs can predict AKI 
before surgery independently of its severity. This worthy information could have a great impact in 
clinical practice by allowing the detection of patients with risk of AKI development after surgery and 
the application of prevention strategies.  
However, these high predictive values are not observed in serum miRNAs determination 
immediately after surgery, when AUC values obtained vary from 0.6 to 0.7. This drastic change in 
discriminative ability is probably due to the dilution factor produced by the intense hydration 
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treatment to which operated patients are submitted during surgery, probably requiring a correction 
factor, such as normalization by hematocrit. 
In addition, our correlation studies demonstrate that miR-26b, miR-146a, miR-93* and miR-
127-3p progressively decrease their expression levels in serum during the days prior to AKI diagnosis 
by serum creatinine. These data demonstrate that serum miRNAs can detect AKI development 
several days before serum creatinine. It is important to notice that miR-146a, which demonstrated a 
very high diagnostic potential in ICU patients, presents here a strong and significant downregulation 
during previous days to AKI. These data confirm that this miRNA could be considered as a robust and 
early AKI diagnostic tool in several clinical contexts.   
As indicated in previous sections, AKI is a dynamic syndrome which includes progressive 
structural and functional damage and whose appropriate treatment requires a complete information 
collection from early injury to long-term outcomes.  
Based on this dynamic view of AKI, Pickering and Endre developed the concept of Phase-
Specific AKI Biomarkers. Phase-1 Biomarkers identify risk of AKI allowing the application of 
preventive strategies. In this regard, our panel of miRNAs has demonstrated the ability to identify 
risk patients before surgery. On the other hand, Phase 2 Biomarkers are important for injury 
identification, which is essential to precipitate early therapeutic interventions.  Our data 
demonstrate that miRNAs progressively decrease their expression levels in serum days before AKI 
diagnosis by creatinine. Phase 3 Specific Biomarkers are able to monitor injury and repair. In this 
regard, our results indicate that miRNAs expression levels correlate with severity of renal injury and 
they also indicate different recovery degrees. Finally, Phase 4 Specific Biomarkers permit the 
monitoring of AKI outcomes (Pickering JW and Endre ZH, 2009b). Our data suggest that serum 
miRNAs could indicate a possible long-term evolution to other renal pathologies, particularly CKD. 
Other outcomes such as mortality or RRT requirement need to be further investigated in following 
studies.  
Based on the above discussed features, miRNAs have been unveiled as complete and 
dynamic biomarkers able to detect almost all the structural and functional features included in the 
complex pathophysiology of AKI, from risk identification to long-term evolution or outcome.  
Despite all these promising results, the present work presents several limitations that should 
be solved in further studies. First, this is a pilot study with a limited number of patients. Further 
studies should be done increasing the number of patients included in each context and in 
collaboration with other hospitals to confirm these data and to give an increased statistical 
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significance to our results. Moreover, prospective studies need to be performed to explore the 
association of miRNA expression with worse prognosis and outcomes such as RRT requirement or 
mortality. Prognostic value such as acute-on-chronic kidney disease prediction, kidney function after 
renal transplant or monitoring responses to therapies needs to be also investigated. 
On the other hand, as in the majority of AKI biomarker studies, serum creatinine has been 
used as the gold standard for AKI diagnosis in this work. Despite the widely known limitations of this 
marker and the multifaceted nature of AKI, changes in serum creatinine levels remains the main 
criteria for phenotyping this disease. Therefore, in the absence of other potentially more informative 
standard such as tissue examination, the use of creatinine as a comparator is not unreasonable, as 
we have done in this work.  
It is important to notice that comparison with creatinine information is not criteria enough to 
accept or reject a new biomarker, since new biomarkers are indeed providing new information that 
can be initially difficult to understand and interpret. Indeed, recent works are pointing out the 
existence of subclinical AKI episodes in which kidney suffers structural but not functional damage 
(Murugan R and Kellum JA, 2011). These cases are currently undetected by serum creatinine and 
could be determinant for future more severe AKI episodes or chronic diseases. New biomarkers 
could contribute to improve subclinical AKI diagnosis indicating renal damage without increase in 
creatinine levels.  
On the other hand, current biomarker studies rely on ROC statistical analysis to assess 
discriminative ability and diagnostic potential. However, several works have reported that AUC-ROC 
values are a relatively insensitive metric since extremely robust associations between the outcome 
and minimal overlapping are required to significantly improve AUC values. Based on this feature, 
increasing evidence suggest that novel statistical prediction models to ascertain clinical value could 
be needed for these studies (Pencina MJ. et al., 2008; Pickering JW and Endre ZH, 2012).  
Although miRNAs present a very high diagnostic value by themselves, several studies have 
pointed out that combination of several biomarkers significantly improves diagnostic precision. For 
instance, combination of NGAL, NAG and KIM-1 in a logistic regression model increases predictive 
ability from individual AUC values around 0.6 to 0.78 in the combined model (Han WK et al., 2009). In 
this regard, biomarkers which are generated in a similar biological pathway can present a very high 
probability of colinearity (Siew ED, et al., 2011). Due to this, a combination of biomarkers, including 
miRNAs, with different biological properties and origin and matching different pathophysiological 
pathways could avoid information overlapping offering integrated diagnostic information of the 
pathology. 
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Despite the advantages of all the biomarkers currently in development, none of them have 
demonstrated yet a clear and unmistakable clinical advantage compared to serum creatinine. Thus, 
novel biomarkers could be considered as a tool for complementing serum creatinine rather than to 
replace it. Novel future AKI classifications have been proposed in which two domains can be found, 
one for function measuring, based on serum creatinine, and the other for damage estimation based 
on changes of a panel of biomarkers.  In this theoretical classification, ‘risk’ stage is determined by 
small changes in one marker while ‘failure’ might require more than one changes in several markers 
or possibly large changes in a single marker (Murugan R and Kellum JA, 2011).  
 
In summary, in this work we identified for the first time a novel role of miR-127 as a critical 
regulator of cell-cell and cell-matrix adhesion in proximal tubule cells response to I/R. Additionally we 
unveiled a new regulation of this miR-127 through HIF-1α. Moreover, a novel target gene for this 
miRNA was also elicited: KIF3B, with important implications in cell endocytosis. As cell adhesion and 
cell trafficking are essential for proximal tubule epithelial structure and function, miR-127 and KIF3B 
could be considered as key molecules for renal ischemic damage management. In addition, a panel of 
serum microRNAs, including miR-127, has been unveiled as novel biomarkers of AKI. Serum miRNAs 
present a high diagnostic potential in ICU patients and their expression levels correlate with AKI 
severity. Serum miRNAs could be also potential biomarkers of different recovery degrees and 
differentiate between AKI etiologies and pre-renal or intrinsic origin. Indeed, serum miRNAs 
associated to ischemic AKI can determine AKI predisposition in a cohort of patients submitted to CPB. 
Serum levels of these miRNAs progressively decrease days before AKI diagnosis, indicating their 
potential as early injury biomarkers.  
This work constitutes an example of translational research from bench to the bedside in 
which molecular mechanism of AKI studied in experimental in vitro and in vivo models, can be useful 
in clinical context. Thus, miR-127 has been identified in vitro and in vivo as a key mediator of renal 
responses to I/R injury and is also a biomarker of ischemic AKI showing a high early diagnostic and 
predisposition identification value. It is important to notice that, through intellectual property 
application for the miRNA combination identified and validated here, we are trying to generate an 
AKI diagnostic kit for clinical use.  
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1. rno-miR-127 and its human homologous hsa-miR-127-3p are induced in an in vitro model of 
Hypoxia/Reoxygenation (H/R) in proximal tubule cells and in an in vivo model of renal 
ischemia/Reperfusion (I/R) in rat. This induction is regulated by HIF-1α, among other 
mechanisms.  
2. rno-miR-127 induction during H/R prevents actin depolimerization and cell adhesion alterations 
by reducing Focal Adhesion Complexes disassembly and Tight Junction disorganization. 
3. KIF3B is a real target of rno-miR-127 in proximal tubule cells during H/R, with important 
implications in proximal tubule cell trafficking.  
4. Serum miRNAs miR-127-3p, miR-101-1, miR-210, miR-126, miR-26b, miR-29a, miR-146a, miR-
27a, miR-93* and miR-10a are diagnostic biomarkers of AKI in ICU patients compared to healthy 
controls. 
5. miR-210, miR-126, miR-29a and miR-146a expression levels correlate with AKI severity and can 
discriminate between pre-renal and intrinsic AKI. 
6. miR-26b, miR-146a, miR-93* and miR-127-3p indicate AKI development before serum creatinine 
increases, becoming as early biomarkers for AKI diagnosis in a cohort of patients submitted to 
cardiac surgery with cardiopulmonary bypass. 
7. miR-26b, miR-27a, miR-93* and miR-127-3p, estimated in serum samples obtained before 
cardiac surgery, are biomarkers of AKI predisposition in this clinical situation. 
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